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Pandemic influenza is a perennial threat to humanity and occurs when 
novel influenza A viruses acquire the ability for sustained inter-human 
transmission and emerge within an immunologically naïve human population. 
Of all influenza subtypes, highly pathogenic avian influenza H5N1 is of 
particular concern due to the high fatality rate. Current strategies against 
influenza rely heavily on vaccine and antiviral drugs, however the antigenic 
diversity among H5N1 viruses and emerging antiviral resistance present a 
major hurdle in pandemic preparedness plans.  
Combination passive immunotherapy, which is the use of non-competing 
neutralizing antibodies, has been proposed as a viable alternative to provide 
broad protection against heterologous viruses. This approach necessitates 
the pre-pandemic production, characterization and epitope mapping of 
potently neutralizing monoclonal antibodies (MAbs). It is envisioned that 
through the combined efforts of different groups, a library of well-
characterized influenza MAbs would be available and would facilitate 
selection of an appropriate MAb cocktail against the pandemic strain.  
Working towards this aim, this study characterizes two such MAbs, 9F4 and 
4F3, which were selected based on their ability to broadly neutralize H5 from 
multiple clades. 9F4 was found to be a homosubtypic MAb while 4F3 
displayed the ability to bind to H7 subtypes belonging to the Eurasian lineage 
that have also caused disease in humans.  
As 9F4 demonstrated strong neutralizing potency, it was converted from 
mouse IgG2b to mouse-human chimeric IgG1 and IgA1. These chimeric MAbs 
were found to retain varying degrees of binding and neutralizing activity. 
 ix 
 
Importantly, chimeric IgG1-9F4 did not induce immunotoxicity in humanized 
mouse model. 
Finally, the epitope mapping of 9F4 was extended and compared to other 
well-characterized anti-H5 MAbs. The method described in this thesis may 
also be readily adopted for other influenza viruses with pandemic potential. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Influenza A viruses 
Influenza viruses belong to the Orthomyxoviridae family, which 
consists of the 6 genera: Influenzavirus A, B and C, Thogotovirus, Isavirus 
and Quajavirus (Palese and Shaw 2007; Presti et al. 2009). The three genera 
of Influenzavirus are antigenically categorized according to their nucleoprotein 
and matrix proteins. Of these, only Influenza A and B viruses cause 
significant human disease and only Influenza A viruses (IAV) are known to 
cause pandemics. IAV are highly heterogeneous and contagious pathogens, 
capable of infecting a wide range of animal hosts. The diverse viral gene pool 
and its large animal reservoir make eradication of IAV unlikely and the 
potential for interspecies transmission presents a constant public health threat 
to humans, as evidenced by prominent outbreaks of avian influenza in recent 
years. 
IAV are pleiomorphic, single stranded negative sense RNA viruses. Their 
RNA genome consists of 8 segments (Palese and Schulman 1976; Ritchey et 
al. 1976), which encode for at least 13 proteins (Table 1.1). Each RNA 
segment associates with multiple copies of nuclear protein (NP) and the 
heterotrimeric viral transcriptase (comprising PB1, PB2 and PA) to form the 
ribonucleoprotein (RNP) complex (Zheng and Tao 2013). The RNPs are 
packed in a viral core made up of matrix protein 1 (M1). M1 also associates 
with small numbers of the nuclear export protein (NEP), previously 
designated as non-structural protein 2, NS2) (Yasuda et al. 1993). The viral 
core is enveloped by a lipid membrane, consisting of both cholesterol 
enriched lipid rafts and nonraft lipids derived from host cells during the 
budding process (Rossman and Lamb 2011). Embedded in the lipid 
membrane are three proteins: hemagglutinin (HA) and neuraminidase (NA) 
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surface glycoproteins, and the ion-channel protein matrix protein 2 (M2). A 
schematic of the influenza virus is shown in Figure 1.1. 
 
 
Figure 1.1: Schematic of IAV [Taken from (Medina and García-Sastre 2011)]. 
The surface glycoproteins HA and NA, as well as M2 are embedded in the 
virus envelope, with HA being the most abundant. The negative sense-ssRNA 
segments associate with NP and the viral transcriptase (comprising PB1, PB2 
and PA) as RNPs. M1 associates with the viral envelope, the RNPs and NEP 

















Polymerase subunit, involved in elongation of nascent viral mRNA 
Non-essential to virus viability, role in virus replication (Wise et al. 2009) 




Polymerase subunit, possesses endonuclease activity 
Represses host cell response, involved in host cell shut off (Jagger et al. 2012) 





Involved in viral RNA replication and host-range determination 
6 NA 
 
Type II surface glycoprotein, possesses sialidase activity for the release of progeny virions 
Aids in penetration of mucin barrier during infection initiation (Matrosovich et al. 2004) 















Matrix protein, most abundant viral protein. Maintains rigidity of membrane and shape of virus particles 
(Nayak et al. 2009) 







Multifunctional non-structural protein, IFN agonist, repressor of host protein synthesis. Expressed 
abundantly in infected host cell. 
 
Mediates nuclear export of viral RNPs to the cytoplasm 
Table 1.1 (continued from previous page): Summary of proteins encoded by the different IAV gene segments. [Based on (Palese 




1.2 Classification of IAV 
 
HA and NA are the major surface glycoproteins and consequently 
determine the antigenic subtypes of the virus. Presently, there are 18 HA 
(designated H1-H18) and 11 NA (designated N1-N11). The first 16 HA and 9 
NA subtypes have been isolated from wild aquatic birds of the orders 
Anseriformes (e.g. swans, ducks and geese) and Charadriiformes (e.g. 
waders, terns and gulls). These birds are considered to be the natural 
zoonotic reservoir and their ability to co-host multiple IAV contributes to re-
shuffling of gene segments between two or more IAV subtypes. This process 
(antigenic shift) leads to the emergence of novel reassortant viruses and is 
the basis for major antigenic diversity (Causey and Edwards 2008). The lack 
of proof-reading ability of the viral polymerase and the intrinsic instability of 
the single stranded RNA genome leads to further diversity as IAV are subject 
to rapid mutation. The accumulation of point mutations combined with natural 
selection drives antigenic drift as mutations with high fitness gain dominance 
over other genetic variants (Chen and Holmes 2006). Recently, H17N10 and 
H18N11 viruses have been identified in bats by next generation sequencing. 
However, it is critical to note that structures of bat-derived HA and NA differ 
significantly from H1-16 and N1-9 respectively. H17 and H18 do not bind 
sialic acid receptors; N10 and N11 lack sialidase activity; and furthermore, 
these viruses remain unviable. In addition, both H17N10 and H18N11 have 
not been discovered in birds to date. Thus, it is uncertain if these bat-derived 
IAV-like genomes represent true IAV or how they may contribute to the 
overall IAV ecology (Tong et al. 2012; Wu et al. 2014). 
Avian influenza infections are usually asymptomatic in wild birds and 
consequently, these viruses are known as lowly pathogenic avian influenza 
(LPAI). When introduced into poultry, LPAI may be asymptomatic or cause 
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mild and self-resolving illnesses. Some strains of H5 and H7 cause disease 
and death in wild aquatic birds and these are known as highly pathogenic 
avian influenza (HPAI). HPAI strains evolve from non-pathogenic precursors 
and differ from LPAI in the composition of their cleavage site, at which 
precursor HA (HA0) is cleaved into disulphide linked HA1 and HA2 subunits. 
As depicted in Figure 1.2, HPAI viruses contain a polybasic cleavage site, 
which is recognized by ubiquitously expressed subtilisin-like enzymes. This 
enables infection of multiple organs and leads to systemic infection in the 
avian host. On the other hand, the cleavage site of LPAI and seasonal human 
IAV lack this series of consecutive basic residues and its cleavage site is 
recognized by trypsin-like proteases that are mainly limited to the intestinal 
and respiratory tract (Bertram et al. 2010). In avian hosts, transmission of 
LPAI is achieved via the fecal-oral route whereas virus shedding from the 
respiratory tract is more pronounced in HPAI and is associated with 
adaptation to terrestrial poultry. The Gs/Gd lineage of H5N1 that arose in 
southern China (section 1.3.2) is the only HPAI lineage that has established 






Figure 1.2: HA determines the pathogenicity of IAV in birds [Taken from 
(Horimoto and Kawaoka 2005)]. Post-translational cleavage of HA0 generates 
disulphide linked HA1 and HA2 and activates the fusion domain (shown in 
grey), which mediates viral and host membrane fusion and therefore 
determines viral infectivity. The LPAI cleavage site is often monobasic or 
lacks multiple consecutive arginine residues. This limits the HA activation to 
proteases located in the respiratory and intestinal tract (depicted as blue stars) 
and results in localized infection. In contrast, the additional arginine residues 
in the HPAI virus cleavage site broaden protease reactivity. HPAI HA is 
activated in multiple organs and results in lethal systemic infection. 
 
1.3 Interspecies transmission 
Other than wild aquatic birds, IAV also infect a variety of animals 
including humans, pigs, horses, sea mammals, domestic birds and terrestrial 
poultry. Introduction of IAV in all of these species has been phylogenetically 
traced to aquatic birds as source of infection, either directly or via an 
intermediary host (Figure 1.3). The susceptibility of pigs to avian, swine and 
human viruses allows for genetic reassortment during co-infection of the 
viruses and enables pigs to act as a “mixing vessel” through which novel IAV 
can be transmitted to humans (Ma et al. 2008). Thus, from a human public 
health perspective, avian and swine reservoirs are the most important 
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sources of IAV gene segments from which novel IAV capable of human 
infection may emerge.  
 
 
Figure 1.3: Interspecies transmission of IAV [Taken from (Wahlgren 2011)]. 
Dotted lines depict occasional transmission events while solid arrows depict 
frequent or confirmed transmission events. Aquatic birds are thought to be the 
primordial reservoir for all other avian and mammalian IAV.  
 
1.4 Influenza in humans 
In humans, IAV cause widespread respiratory illnesses ranging from 
mild symptoms such as fever, cough and sore throat (known as influenza like 
illness, ILI), to severe complications such as pneumonia, respiratory distress 
and death. Transmission between humans occurs in three main ways: i) 
inhalation of contaminated respiratory droplets into the upper respiratory tract 
(droplet transmission), ii) inhalation of contaminated aerosols into the lower 
respiratory tract (aerosol transmission), or iii) the transfer of virus particles to 
the upper respiratory tract mucosa (contact transmission) (Killingley et al. 
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2013). While good personal hygiene and social distancing is recommended to 
curb the spread of disease, the potential ability of the viruses to persist in 
settled droplets presents difficulties in infection control, particularly during the 
peak of seasonal and pandemic influenza (Weber and Stilianakis 2008). 
The main public health burden posed by IAV is the ability of IAV to evade 
previous immunity through antigenic drift and shift as they continuously 
circumvent herd immunity from previous infection or vaccination. Antigenic 
drift of human IAV results in seasonal epidemics in temperate countries and 
more continuous circulation within the tropics. These epidemics are 
characterized by widespread morbidity among all population groups and 
results in 3-5 million severe cases annually, which are generally confined to 
the elderly. Apart from the elderly, young children and those with comorbid 
diseases are also at risk of disease complications. The annual global mortality 
rate is estimated at 500,000 deaths and this situation represents baseline 
interpandemic influenza (Bridges et al. 2002). 
Since the 20th century, four influenza pandemics have occurred, each 
resulting in greater morbidity and excessive mortality compared to seasonal 
influenza (Figure 1.4). Pandemics may arise due to direct transmission of 
avian IAV viruses followed by adaptation in man, as with the 1918 H1N1 
pandemic; or due to the reassortment of avian and circulating human viruses, 
as with the 1957 H2N2 and 1968 H3N2 pandemics. In 2009, a triple 
reassortant virus of avian, swine and human origin emerged and caused the 
first pandemic of the 21st century. The HA and NA of this virus, termed 
A(H1N1)pdm09, was antigenically similar with the 1918 H1N1 strain but not 
the drifted circulating seasonal H1N1. Since the 1918 H1N1 virus re-emerged 
in 1977 as shown in Figure 1.4, the older generations maintained some 
immunity against A(H1N1)pdm09, and the pandemic was skewed towards the 
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younger working population and children who were exposed to drift variants 
but not the original 1918 virus (Nishiura et al. 2010; Peiris et al. 2009). The 
A(H1N1)pdm09 pandemic was also less severe than 1918 H1N1 as 
A(H1N1)pdm09 lacked virulence markers in other gene segments compared 
to 1918 H1N1 virus.  
Knowledge on how pandemic viruses emerge and the underlying molecular 
mechanisms that determine degree of virulence is incomplete. The current 
understanding is that host switch and virulence determinants are polygenic, 
involving the interplay of the different gene segments. Although several gene 
markers associated with human adaptation, transmission and virulence have 
been identified, how mixed inheritance of these genes affects overall viral 
fitness and health status of the human host remains unpredictable. 
 
 
Figure 1.4: Influenza pandemics of the 20th and 21st century with estimated 
mortality rates. Vertical arrows depict antigenic shift, coinciding with the 
occurrence of 4 the pandemics in the 20th century and the first pandemic in 
the 21st century. Horizontal arrows depict antigenic drift during continual 
circulation in man. In 1977, the H1N1 virus re-emerged and co-circulated with 
H3N2 as seasonal influenza until 2009, where the novel A(H1N1)pdm09 
replaced it as the dominant circulating H1N1 strain. 
 11 
 
1.5 Avian Influenza with pandemic potential 
 
Although any IAV subtype has the potential to cause the next 
pandemic, emphasis has been placed on avian IAV that have caused direct 
zoonotic infections in humans (Table 1.2). Of these, both HPAI H5N1 and 
A(H7N9) (henceforth H7N9) have received considerable attention due to the 
large number of cases in humans, which may suggest gradual adaptation 
towards humans.  
IAV replicate in columnar epithelial cells throughout the respiratory tract. 
Infection begins by binding to sialyloligosaccharide host cell receptors via HA. 
These host receptors are categorized according to the linkage of N-
acetylsialic acid to a terminal galactose residue. Avian IAV have a binding 
preference towards α2,3Gal-linked sialic acid, human IAV prefer α2,6Gal-
linkages and swine IAV bind to both α2,3Gal- and α2,6Gal-linked sialic acid. 
In humans, α2,6Gal containing receptors predominate on epithelial cells of 
the nasal mucosa, paranasal sinuses, pharynx, trachea and bronchi. On the 
other hand, α2,3Gal  are found in the lower lung, on non-ciliated cuboidal 
epithelial cells at the terminal bronchioles, type II- pneumocytes on the 
alveolar wall lining and alveolar macrophages (Shinya et al. 2006; van Riel et 
al. 2006). The pattern of receptor distribution explains the lower lung 
pathology seen in human infections of HPAI H5N1 (Beigel et al. 2005; 
Uiprasertkul et al. 2005). The general restriction of H5N1 infection to the 
lower lung has also been suggested to contribute to inefficient human 
transmission; consequently, H5N1 infection remains sporadic and human-to-
human transmission is impeded. In contrast, human isolates of H7N9 are able 
to bind both α2,3Gal- and α2,6Gal-linkages, but with a greater preference for 
α2,3Gal receptors. As such, H7N9 is associated with a higher rate of avian- 
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to- human transmission but human-to-human transmission remains restricted 
(Zhou J. et al. 2013). 



















H7N2 America 2003 1* 0 Pneumonia (Ostrowsky et 
al. 2012) 
H7N3 Mexico 2012 2 0 Conjunctivitis (Lopez-Martinez 






11 0 ILI ( Peiris et al. 
1999; Wei and 
Koh 2013) 














H7N9 China 2013 450 165 Severe 
pneumonia 
(WHO 2014b; 
WHO 2014c)  




H6N1 Taiwan 2013 1 0 ILI with 
shortness of 
breath 
(Shi W. et al. 
2013) 
Table 1.2: Cases of avian-to-human transmission. Majority of the spillover 
events were confined to small number of cases and associated with minor 




1.5.1 Pandemic Potential and Evolution of HPAI H5N1 
Zoonotic infections of HPAI H5N1 continue at low frequency and 
predominantly affects children and young adults (Fiebig et al. 2011). HPAI 
H5N1 is particularly worrisome due to the high case fatality rate, widespread 
geographical circulation (Figure 1.5.1) and ability to cause asymptomatic 
infection in pigs (Nidom et al. 2010). With few exceptions of suspected limited 
human-to-human household transmission (Butler 2006; Wang H. et al. 2008), 
the human cases of H5N1 are largely due to direct avian-to-human 
transmission and remain confined to relatively small clusters. However, recent 
studies demonstrating that only a few mutations could be sufficient for the 
efficient and sustained respiratory droplet transmission of a wholly H5N1 virus 
or experimental recombinant, indicating that a pandemic of H5N1 may not 
require reassortment with human IAV or participation of intermediate 
mammalian host (Imai et al. 2012; Herfst et al. 2012). In other words, 
antigenic drift of currently circulating H5N1 viruses alone is a pandemic risk. 
This finding, combined with the exceptionally high case-fatality rate of nearly 
60% sends a portentous warning to public health. Juxtaposing the 1918 H1N1, 
which had an estimated case fatality rate of 3%-6% (Taubenberger and 
Morens 2006) and coupled with an increasingly populous and globalized 
world, the scale and severity of a H5N1 is potentially unprecedented in the 
history of human influenza. The World Bank estimates that the loss to global 
economy could be up to three trillion dollars, should such a pandemic occur 
(The World Bank 2012). 
HPAI H5N1 initially evolved by antigenic shift and then more recently by 
antigenic drift. Prior to 1996, cases of HPAI H5N1 in birds were isolated and 
there was no evident threat to humans.  In 1996, the HPAI H5N1 (designated 
Gs/Gd virus) caused an outbreak in geese farms in Guangdong, China, with 
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moderate mortality. This precursor H5N1 virus presumably acquired internal 
genes from a quail H9N2 virus and neuraminidase gene from duck H6N1 
virus that were co-circulating within aquatic bird reservoirs (Guan et al. 1999; 
Hoffmann et al. 2000), while retaining a similar H5 HA (de Jong et al. 1997; 
Bender et al. 1999; Xu et al. 1999; Shortridge et al. 1998). In 1997, this 
recombinant virus caused widespread mortality in terrestrial poultry and 
transmission to humans, killing 6 out of 18 infected people.  
While the outbreak was successfully contained and the Gs/Gd-like virus 
eradicated through culling of domestic poultry in Hong Kong, several 
reassortants containing the same H5 HA but various internal genes continued 
to emerge in aquatic bird populations. By 2002, 8 new genotypes emerged 
and replaced all precursor genotypes (Table 1.5.1). Of these, genotype Z 
gained an adaptive advantage and established dominance in southern China. 
In 2002, genotype Z caused widespread mortality among wild, domestic and 
exotic waterfowl in Hong Kong nature parks. In 2003, H5N1 re-emerged in 
humans in Hong Kong and of the 62 human isolates sequenced, 60 were 
genotype Z while 2 were genotype Z+. Genotype Z then spread in an 
unprecedented fashion across Asia in 2003-2004, causing disease in both 
aquatic and terrestrial birds, eventually leading to avian-to-human 
transmission in Thailand, Vietnam and Indonesia.  
In 2005 and 2006, outbreaks of HPAI H5N1 among wild migratory birds in 
Qinghai Lake, China, led to the geographical expansion of H5N1 to Europe, 
Middle East and Africa. The establishment of endemicity in wild birds and 
poultry in different countries led to distinctive spatio-temporal genetic 
diversification by antigenic drift. A decade after the first human outbreak in 
Hong Kong, representatives from the World Health Organization (WHO), the 
World Organization for Animal Health (OIE) and the Food and Agriculture 
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Organization of the United Nations (FAO) convened a H5N1 evolution 
working group to create a unified system of classifying H5N1 viruses 
according to the phylogenetic relationship of the HA gene to the progenitor 
Gs/Gd viruses, which were re-designated as clade 0 (WHO/ OIE/ FAO H5N1 
Evolution Working Group 2008). The group identified 10 unique first-order 
clades (0-9), with some clades consisting of second- and third- order as the 
virus continued to evolve within each first-order clade. The rapid geographical 
expansion and continual establishment of higher-order-clade viruses in 
various enzoonotic foci led to designation of fourth- and fifth- order clades in 
the latest 2014 update (WHO/ OIE/ FAO H5N1 Evolution Working Group 
2014) (Figure 1.5.2). Most viruses used for determining such phylogenetic 
relationship are from avian sources and have not yet caused human disease. 
Until 2009, human infections were caused by viruses from clades 0, 1, 2.1, 
2.2, 2.3 and 7, with clade 2 viruses causing majority of the cases. From 2010 






Figure 1.5.1: Geographical distribution of H5N1 infections in humans as of 8 
January 2014 [Taken from (WHO 2014c)]. 
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Figure 1.5.2: Phylodynamics of HA gene. Diagram shows phylogenetic tree 
and geographic locations of circulating HPAI H5N1 viruses. Newly designated 





















clades as of 2014 are highlighted in green [adapted from (WHO/ OIE/ FAO 
H5N1 Evolution Working Group 2014)]. 
 
 
1.5.2 Emergence and Pandemic Potential of LPAI H7N9 
As shown in Table 1.3, avian influenza bearing H7 HA has caused 
sporadic illness in humans since 1996. The human infections resulted in mild 
symptoms with the exception of 1 death in Netherlands. Each outbreak was 
isolated and closely associated with exposure to sick poultry. 
In early 2013, a novel avian influenza H7N9 emerged in humans in China. 
Although there is no evidence of sustained human-to-human infection, the 
outbreak was rampant and cases were reported from 13 
provinces/municipalities in eastern China. Unlike previous H7 outbreaks, 
H7N9 does not appear to cause disease in poultry, possibly owing to the lack 
of polybasic cleavage site in HA (Gao et al. 2013). It is therefore difficult to 
establish a clear epidemiological link between poultry and human cases. 
Although many patients visited live poultry markets prior to disease onset, 45% 
of patients surveyed reported no contact with poultry (Liu et al. 2014). ILI has 
been detected in a small number of young adults and children infected with 
H7N9 and severe disease is more common in the elderly with underlying 
comorbidities. Clinical outcome of severe H7N9 infection is similar to H5N1, 
with progressive diffuse lung inflammation, acute respiratory distress 
syndrome (ARDS) and multi-organ failure. Although ex vivo studies indicate 
that H7N9 can infect and replicate efficiently in the lower lungs (Chan et al. 
2013), it remains difficult to attribute pneumonia to either primary virus 
infection or secondary bacterial superinfection  (Yu et al. 2013). 
The 2013 outbreak is defined by two epidemic waves, the first wave occurred 
from February to May 2013 with a total of 133 cases reported. The number of 
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cases decreased during summer and a second wave was detected from 
October 2013, coinciding with the return of cooler temperatures (Saey 2014). 
As of January 2014, a total of 450 laboratory confirmed cases has been 
reported with case fatality rate of 36% (WHO 2014e).  
All currently detected H7N9 viruses are genetically similar with little variation 
from A/Anhui/1/2013(H7N9) virus, which has been proposed for vaccine 
development (WHO 2013). The homogeneity and eruption of human cases 
within a short span of time suggests that the H7N9 is widespread within its 
natural reservoir. H7N9 is a reassortant with the H7 gene originating from 
A(H7N3) viruses circulating in ducks in Zhejiang, China; the H9 gene from 
A(H7N9) circulating in wild birds in China and Korea; and the 6 internal genes 
from A(H9N2) viruses circulating in poultry in east Asia (Chen et al. 2013; 
Gao et al., 2013; Liu et al. 2013). 
1.6 IAV infection and immunity 
In humans, influenza infection begins in the respiratory tract, where it 
is localized in most cases. IAV enter the host via oral or nasal cavities and 
must penetrate the mucus layer before attaching to and infecting the 
underlying epithelial cells and spreading to other non-immune and immune 
cells in the respiratory tract. After binding to host cell receptors, the virus 
particles are endocytosed in a clatharin-dependent manner and the low pH 
environment of the endosome causes HA to undergo a drastic conformation 
change, enabling it to mediate fusion of viral and host endosomal membranes. 
The RNPs are released into the cytoplasm and enter the nucleus where 
transcription and replication of the viral genome ensues. 
Upon infection, the airway epithelial cells elicit innate responses that are 
critical in limiting widespread infection and in initiating virus-specific adaptive 
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immunity. The clinical outcome of the human host depends on the balance of 
2 broad, and sometimes opposing, homeostatic strategies: i) antiviral 
resistance and ii) the ability to minimize immune-mediated pulmonary injury 
(disease tolerance and airway repair).  
Innate immune responses that resist viral burden but induce symptoms of 
disease begin when pattern recognition receptors (PRRs) of airway epithelial 
cells, dendritic cells (DCs), macrophages and pneumocytes, recognize IAV 
RNA and signal the production of type I interferons (IFNs), other chemokines 
and pro-inflammatory cytokines. PRRs detect viral antigens within the 
endosomes (e.g. Toll-like receptors: TLR3 and TLR7) or within the cytosol 
(e.g. RIG-I and NLRP3). The production of type I IFNs induces the 
upregulation of a group of genes known collectively as IFN-stimulated genes 
in neighboring cells to produce a pro-inflammatory and antiviral state. For 
example, IFN induced Mx genes directly inhibit the transcription of influenza 
gene segments (Pavlovic et al. 1992; Turan et al. 2004). Chemokines recruit 
additional immune cells to the site of infection, where natural killer (NK) cells 
target and kill IAV-infected epithelial cells within the airways. The recruited 
neutrophils and monocytes, together with alveolar macrophages clear away 
cellular debris. Collectively, these responses contribute to viral clearance but 
are accompanied by local and systemic inflammation and the induction of 
fever. However, complete viral clearance requires the adaptive immune 
response as IAV have evolved to counter or hijack innate host responses and 
infection may become established despite these defenses. For example, IAV 
NS1 protein inhibits IFN response (Kochs et al. 2007); NS1 also interferes 
with RIG-I ubiquitination and blocks downstream antiviral signaling (Gack et al. 
2009); full length PB1-F2 translocates to and fragments the mitochondria, 
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suppressing both RIG-I and NLRP3 inflammasome signaling (Yoshizumi et al. 
2014). 
Signaling pathways induced by TLR7, NLRP3 and pro-inflammatory cytokines 
(e.g. IL-1, IFN and IL-6) promote T cell activation and B cell antibody 
responses. Migratory respiratory DCs accumulate in the lymph nodes and 
stimulate naïve T cells (such as CD4+, CD8+ and Treg) via IAV antigen 
presentation and cross-talk. Following their encounter with foreign antigen, T 
cells undergo activation, proliferation and differentiation to become virus-
specific effector T cells. These effector T cells migrate to the site of infection 
and mediate viral clearance by i) direct lysis of infected cells through the 
exocytosis of perforin and granzyme by CD8+ T cells (CTL response); ii) 
inducing apoptosis of infected cells; and iii) modulating inflammation by 
producing both pro-inflammatory and regulatory cytokines. The contribution of 
T cell response to disease tolerance is currently subject to intense research 
as dysregulation of inflammation, hypercytokinaemia and pulmonary injury 
are associated with severe influenza disease such as those infected with 
HPAI H5N1 (Peiris et al. 2004; To et al. 2001) and H7N9 virus (Chen et al. 
2013; Zhou et al. 2013). 
CTL response in IAV infection is directed mainly towards internal viral 
antigens and may play a role in conferring some degree of cross protection 
against multiple influenza subtypes. However, viral clearance by CTL alone is 
insufficient. In IAV infection, viral clearance is associated with efficient B cell 
response, with the generation of specific neutralizing serum antibodies. The 
activation of T- helper (CD4+ Th) cells leads to germinal centre formation and 
antibody class switching in the B cell regions of mucosa-associated lymphoid 
tissues (MALT). As antibody production takes several days to develop, 
protection against viral load during primary exposure is less efficient. IAV-
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specific IgM antibodies are rapidly induced as they are expressed without 
undergoing isotype switching and are indicative of primary infection 
(Burlington et al. 1983). Studies following the immune response to parental 
vaccination or natural infection to seasonal IAV demonstrate that sero-
conversion occurs rapidly, with serum IAV-specific IgA and IgG peaking within 
4-6 and 8-9 days after infection respectively. Protection against IAV in the 
upper respiratory tract is mainly conferred by polymeric IgA antibodies, which 
are also produced locally by sub-epithelial antibody secreting cells. These IgA 
producing plasmablasts increase in the upper respiratory tract within a week 
of infection (Wrammert et al. 2011; Brokstad et al. 1995). IgG antibodies 
transudates from the bloodstream into the respiratory mucosa and confer 
protection mainly in the lower respiratory tract. Both IgG and IgA antibodies 
are found in the lower respiratory tract, with IgG being the more abundant. 
The systemic and local antibody responses coincide with recovery and 
continue to persist for several weeks after the onset of symptoms. In 
experimental mice model, the humoral response is long-lived, persisting at 
elevated levels up to 18 months post infection or vaccination (Skountzou et al. 
2014). 
The antibody response is polyclonal and protection is conferred mainly by the 
induction of neutralizing serum antibodies towards HA (discussed in 1.6). 
Protective antibody response directed against NA has also been 
demonstrated. These antibodies limit disease severity by contributing to 
antibody-dependent cellular cytotoxicity (ADCC) and prevents the release of 
progeny viruses but do not prevent infection. The role of antibodies produced 
against the other viral proteins during immunization is poorly understood but 
are generally thought to promote protection through CTL via MHCI 
presentation of these viral antigens and/or ADCC.  
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The inability of host response to resist viral load and moderate immune 
responses are hallmarks of severe cases H5N1 and H7N9 infection, which 
are characterized by prolonged and high pharyngeal viral load and 
hypercytokinaemia. Viral load persistence, even during antiviral therapy, 
contributes to an aggravated and prolonged innate immune response also 
known as the “cytokine storm” and is associated with lung injury (Shen et al. 
2014; Rimmelzwaan and Katz 2013). It is estimated that the mean incubation 
period for both H5N1 and H7N9 is 3-4 days; however, the median 
hospitalization-to-death time of H5N1 is 6 days compared to 12 days for 
H7N9. Assessment of primary antibody kinetics against acute H7N9 
demonstrates that neutralizing antibodies peaked at approximately 2 weeks 
after onset of fever in all 6 patients examined while highest fever and 
hypercytokinaemia occurred within 10 days post onset of fever. Viral 
clearance was only achieved at a median of 24 days after onset of fever 
(Huang et al. 2014). Thus, in fatal cases of H5N1 and H7N9, the rapid 
progression of disease means that death usually occurs before a protective 
antibody response can ensue. The protection conferred by antibodies 






1.7 Limitation of current options against pandemic influenza 
 
1.7.1 Vaccination  
According to WHO, vaccination remains “the principle measure for 
preventing influenza and reducing its impact” (WHO 2014d). Vaccination is a 
protective approach as it mimics primary infection but without the 
accompanying disease. It relies on host endogenous antibody response 
during subsequent infection with matching strain and is therefore suboptimal 
among the highest risk group populations with compromised immune systems.  
Seasonal vaccines are trivalent, protecting against two IAV strains (H3N2 and 
H1N1) and one Influenza B strain. Each virus is cultured separately, 
inactivated and then combined. Strain selection is adjusted every year based 
on international surveillance of the previous influenza season. Additionally, 
WHO maintains candidate pre-pandemic seed viruses against H5N1, H7 and 
H9 IAV that may be used for the production of pre-pandemic vaccines. 
However, the cost to grow each virus separately and to update the 
preparations based on surveillance data makes the addition of multivalent 
pre-pandemic strains to seasonal vaccines unfeasible. 
Pre-pandemic vaccines currently under clinical trials may be administered 
either: i) intramuscularly/ intradermally in the form of inactivated whole virus, 
inactivated split virion or inactivated subunit vaccines; or ii) intranasally, in the 
form of live attenuated vaccine. For H5N1 vaccines, the initial poor 
immunogenicity of H5 HA in humans meant that larger vaccine doses were 
required (Treanor et al. 2006; Nolan et al. 2008; Patel et al. 2010), placing 
further constraints on availability. More recent research focusing on improving 
immunogenicity through use of adjuvants (Leroux-Roels et al. 2007; Lopez et 
al. 2013; Leroux-Roels et al. 2010), or highly immunogenic live attenuated 
vaccines (Talaat et al. 2014) show promising results.  
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While in theory pre-pandemic vaccines can offer the advantage of priming 
populations to limit or delay spread of pandemic influenza, the main limitation 
of pre-pandemic plans involving stockpiling of vaccines is the impossibility of 
predicting the next pandemic subtype or strain. In the case of H5N1, most 
trials involve antigen derived from clade 1 and 2 viruses. Although the 
different H5N1 vaccine strains have been reported to induce some level of 
cross-clade reactivity, it remains impossible to completely predict inter-clade 
or inter-subclade cross-protection as these studies are based on selected 
clade representative viruses and may not reflect clade and subclade outliers. 
Finally, the immunogenicity profiles of novel strains are unknown and this 
causes uncertainty with regards to optimal dosage and use of adjuvants 
(Dormitzer 2014). 
Although some vaccines are produced in mammalian cell culture (van der 
Velden et al. 2012), majority of vaccines are being produced in embryonated 
chicken eggs. Such continued reliance impedes scale-up during pandemic 
situations and is affected by vulnerability of chicken embryos to HPAI strains. 
Furthermore, the production of H5N1 vaccines would be limited to high 
containment BSL3 facilities and the potential selection of egg-adapted viruses 
may lead to decreased efficacy if they differ antigenically from circulating 
viruses (Jennings et al. 2008; Rockman and Brown 2010). 
The current annual global capacity for vaccine production is estimated at 
1420 million doses of trivalent vaccines, or approximately 4.2 billion doses of 
15 μg dose of monovalent pandemic vaccines. Assuming that yields for 
pandemic and seasonal vaccine antigens will be similar and that the 
pandemic strain will elicit sufficient immunogenicity using a prime-boost 
strategy comprising two doses of 15 μg, the current capacity will enable 
vaccination of only 2 billion people (Partridge and Kieny 2013). Although use 
 26 
 
of adjuvants may lessen required doses, the current capacity still falls short of 
the estimated global need of 13.4 billion pandemic doses (Friede et al. 2011). 
Further, this capacity refers to production across a span of 12 months and 
supply issues during the surge of the pandemic remains a problem. 
Furthermore, majority of vaccine production occurs in countries within the 
northern hemisphere and vaccine take-up is polarized towards industrialized 
countries (Partridge and Kieny 2013). This leaves poorer countries, notably 
those within Africa, Asia and the Middle East, with limited access to pandemic 
vaccines although the risk of H5N1 outbreaks remains the greatest due to 
endemicity of the viruses within avian populations and the incidence of human 
cases in these countries. 
1.7.2 Antiviral drugs 
Antivirals are particularly important during a pandemic because of it is 
most likely that the pandemic will peak before the specific vaccine becomes 
widely available. There are two classes of anti-influenza drugs available: the 
adamantanes (amantadine and rimantadine) and the neuraminidase inhibitors 
(NAIs, Oseltamivir and Zanamivir). The adamantanes inhibit viral entry by 
blocking the proton-pump activity of M2 thereby preventing HA-mediated 
fusion of viral and endosomal membranes. The NAIs bind to NA catalytic sites 
and prevent viral budding. Both the adamantanes and NAIs are usually 
effective only if they are administered within 48-72 hours of onset of 
symptoms (Davies et al. 1964; Yu et al. 2011), and prior to the onset of 
respiratory failure (Adisasmito et al. 2010). 
The induction of resistance is a critical problem caused by the increased use 
of these antiviral drugs. Transmission of resistant strains from treated patients 
to close contacts eventually leads to prevalence of drug resistance within 
communities. Such prevalence may be induced rapidly, as seen for seasonal 
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influenza: adamatane resistance among H3N2 isolates rose from 1.9% to 91% 
within a 2 year period (CDC 2006) and oseltamivir resistance among H1N1 
rose from 12% to 98.5% in the 2007/2008 influenza season alone (Fiore et al. 
2011). This effect could be more pronounced during pandemic situations, 
when there is widespread reliance on antivirals. 
Treatment of H5N1 patients with adamantanes is not recommended, primarily 
due to antiviral resistance (Schünemann et al. 2007). The S31N mutation in 
the M2 protein confers strong resistance against adamantanes and has been 
detected in isolates from all H5N1 clades (Cheung et al. 2006; He et al. 2008; 
Boltz et al. 2010; Dong et al. 2014; Govorkova et al. 2013). Similarly, H7N9 
bears the S31N mutation (Gao et al. 2013). Other gene markers of 
adamantane resistance, V27A and L26I, have also been detected in 
circulating H5N1 clade 1 and 2 viruses respectively (Cheung et al. 2006; Hurt 
et al. 2007). 
Oseltamivir is indicated in H5N1 treatment as in vitro effectiveness has been 
demonstrated and a reduction in relative risk has been observed in H5N1 
patients receiving treatment. However, drug resistant H274Y strains were 
reported in 3 patients receiving oseltamivir therapy. Other gene markers 
conferring resistance to oseltamivir have been detected in both avian and 
human isolates, particularly within the geographically diverse clade 2 viruses. 
These include V116A, I222L, K150N, S246N, E119A and N294S (Boltz et al. 
2010; Chakrabarti et al. 2009). Additionally, mutations reducing susceptibility 
to oseltamivir (R430W and I223T) have been detected in clade 1 and 2 
viruses (Nguyen et al. 2013). For H7N9, oseltamivir administration coincided 
with reduced viral load and improved clinical outcome. However, the 
oseltamivir resistant mutation R292K has been detected in two severe cases. 
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In one of the two patients, the mutation was only detected after treatment with 
oseltamivir but not before (Hu et al. 2013).   
1.8 The Potential for Antibody Based Therapy  
The limitations of the current prophylactic and treatment options have 
prompted much research into alternative strategies. Since antibodies are 
crucial in the protection against infection, passive immunotherapy has been 
suggested as a viable option. Unlike vaccination, passive immunotherapy 
involves the direct transfer of pre-made antibodies and can therefore be used 
both prophylactically and therapeutically. The approach could also be 
particularly useful for risk group populations who cannot respond well to 
vaccination. For example, vaccine immunogenicity is reduced in the older 
population and this is attributable, at least in part, to immunosenescene 
among the elderly (Chen W.H. et al. 2009). 
The concept of passive immunotherapy was first described by von Behring 
and Kitasano (Winau and Winau 2002) and was used to treat many infectious 
disease until the 1930s including the 1918 Spanish influenza (Luke et al. 
2006). Despite its effectiveness, early passive immunotherapy relied on 
convalescent blood products and was highly variable in terms toxicity, 
antibody specificity and availability. As such, its application became less 
popular with the discovery of antimicrobial agents and the development of 
vaccines (Casadevall et al. 2004). Paradoxically, the current limitations in 
vaccines and antiviral drugs have renewed interest in passive immunotherapy 
for the management of pandemic influenza. Encouragingly, the approach has 
been used to successfully treat H5N1 patients (Zhou B et al. 2007; Wang H. 
et al. 2008) and has been used to improve clinical outcome in patients with 
severe A(H1N1)pdm09 infections (Hung et al. 2011). Furthermore, the advent 
of monoclonal antibody (MAb) technologies and advances in recombinant 
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DNA have provided the platform to produce an unlimited supply of highly 
specific and homologous MAb, thus eliminating the reliance on blood based 
products. Additionally, advances in human B-cell immortalization and display 
technologies now allow for the generation of fully human antibodies. An 
overview of in vitro antibody generation is given in Figure 1.8.1. 
Antiviral antibodies can be classified as homologous, homosubtypic and 
heterosubtypic based on the type of protection conferred. Homologous 
antibodies are highly specific towards single viral isolates while homosubtypic 
protection provides immunity against multiple isolates within the same 
subtype. Heterosubtypic protection is the aim of “universal” strategies against 
IAV as such antibodies are reactive against multiple IAV subtypes. However, 
heterosubtypic antibodies are extremely rare and mainly recognize conserved 
epitopes against inner viral proteins, such as M1, NP, NS1 and the viral 
polymerase. These targets are poorly immunogenic in whole virus 
preparations and generation of MAbs against these inner viral proteins 
require the use of recombinant proteins or synthetic peptides as antigen 
source (He J.L. et al. 2013) for the selection of specific antibody fragments 
from large arrays of antibody libraries. For example, recombinant (r)M1 
(Poungpair et al. 2009; Dong-din-on et al. 2015), rM2 (Pissawong et al. 2013), 
rNS1 (Yodsheewan et al. 2013) and rPB1, rPB2 and rPA (Thathaisong et al. 
2008) have been used for the selection of heterosubtypic and fully human 
single chain antibodies (ScFv) from phage displayed human ScFv libraries. 
However, as these targets are not involved in cell entry, these antibodies 
cannot prevent infection but may be useful in reducing overall disease. 
Furthermore, delivery of therapeutic antibodies to these inner viral targets 
remains challenging since they are not readily exposed to the extracellular 
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milieu. Figure 1.8.2 summarizes the possible viral target for anti-IAV MAbs 
and their mechanism of action.  
 
Figure 1.8.1: Overview of antibody technologies. The generation of antigen 
specific MAbs usually begins with selecting a host that has been exposed to 
the specific antigen either by infection or vaccination. For human hosts, the 
convalescent or immunized serum is obtained and plasma cells are recovered 
either by Ebstein Barr virus (EBV) immortalization or by direct cloning of the B 
cell genes and their expression in vitro. For animal hosts, the spleens are 
harvest and plasma cells are fused with myeloma cells to produced 
immortalized antibody secreting cells. The libraries of immortalized B cells or 
expressed genes are screened using a plethora of techniques for the desired 
antigen-specific MAb. Using recombinant techniques, variable antibody 
domains may be cloned from selected animal MAb and fused with human 
constant domains to give chimeric (-xi-) antibodies. For humanized (-zu-) 
antibodies, only the animal complementarity determining regions (CDR) are 





Figure 1.8.2: Antibody targets during the IAV life cycle [adapted from 
(Neumann et al. 2009). A) IAV bind to epithelial cells by attaching to cell 
surface receptors via HA. Anti-HA antibodies interfere with HA- receptor 
association and prevent virus attachment. B) Virions enter host cell by 
endocytosis and M2 acidifies the endosomes, permitting HA to adopt the 
fusion conformation. Antibodies targeting the M2 ion-channel functions or the 
stem domain of HA potentially inhibit fusion and curb release of RNPs into the 
cytoplasm. C) Viral proteins M2, PA, PB2 and NP are presented to CD8+ T 
cells via MHC I molecules resulting in infected cell lysis. D) Single chain 
antibodies are being developed as intrabodies against a variety of 
cytoplasmic viral proteins to curb virus replication. E) Anti-NA MAbs prevent 











1.9 MAbs against HA 
 
Of the IAV targets, HA is the natural target of neutralizing antibodies 
as it mediates virus attachment and entry and constitutes over 80% of the 
viral envelope proteins. Several groups have demonstrated the protective 
ability of neutralizing MAbs generated against the HA of different influenza 
subtypes in preclinical mouse models. Most of these target the highly 
divergent immunodominant globular head of HA1, which consists of the 
receptor binding site (RBD). The H5 RBD comprises the 190-helix, 130- and 
220-loop, with conserved residues Tyr98, Trp153, His183, Glu190 and Leu194 
forming the receptor binding pocket.  Five major antigenic sites have been 
characterised based on neutralising mouse MAbs against H3N2 (Underwood 
1982; Wiley, Wilson, and Skehel 1981) (Figure 1.9.1). These neutralising 
MAbs block virus-receptor interaction by receptor mimicry or by steric 
hindrances. As a result the globular head is under constant immune pressure 
and this drives antigenic drift. Over time, the virus escapes previous 
protection conferred by MAbs targeting this region. Further, the considerable 
sequence variability among the HA globular head domain of the different 
subtypes restricts the breadth of protection conferred by these antibodies. 
Correspondingly, several potently neutralizing anti-H5N1 targeting the HA1 
domain display exclusive binding to H5 subtype although most bind to several 
H5 clades and subclades (Table 1.4). 
On the other hand, the stem region is less exposed to the extracellular matrix 
compared to the globular head and is thought to be more conserved. 
Conservation of the stem domain is also attributed to the structural confines 
of the fusion machinery. As such, MAbs targeting this region display some 
degree of cross-specificity and neutralise viruses by preventing fusion of host 
and viral membranes. Indeed, several studies have described MAbs to bind to 
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this region and broadly neutralize IAV. However, only one MAb, FI6, has been 
found to neutralize all 16 HA subtypes (Corti et al. 2011). HA subtypes can be 
phylogenetically classified into two groups. Most heterologous stem-targeting 
MAbs described bind to only one HA group and only a handful of MAbs bind 
across groups but are unable to completely neutralize all 16 HA subtypes. 
The low identification of group 1 and group 2 MAbs despite screening of large 
human derived display libraries (examples in Table 1.4) suggest the scarcity 
of completely heterologous IAV MAbs in the human antibody repertoire 
(Clementi et al. 2011; De Marco et al. 2012; Throsby et al. 2008; Ekiert et al. 
2011; Ekiert et al. 2012). Indeed, out of the approximately 104,000 in vitro 
cultivated human plasma cells screened, FI6 was the only MAb with this 
extensive breadth of protection (Corti et al. 2011).  
Despite encouraging preclinical data, the efficacy of these stem-targeting 
MAbs in humans during the course of infection is not yet known. As the stem 
domain is less exposed on the surface of the virus, the dosage of the 
antibodies may have to be increased for therapy of severe H5N1 infections 
where viral load is characteristically rampant. Further, the reasons for the 
HA2 stem domain sub-immunodominance have not been examined 
experimentally. If the conserved nature of the stem domain is due to a lack of 
immune pressure, then the widespread reliance of a single MAb may drive 
the emergence of resistance. Thus, other non-competing H5 MAbs should be 
generated and characterized as evidence suggests that a combination of non-
competing antibodies decreases degree of escape mutants while increasing 






Figure 1.9.1: Known HA antigenic sites based on H3 [Taken from (Mak, Lin, 
and Tan 2014)]. This space filled model of a H3 monomer (Protein Data Bank 
accession 1HGE) was generated using PyMol. Antigenic sites A to E on HA1 




Figure 1.9.2: Classification of HA. Phylogenetic and antigenic properties of 
HA enable the classification into 2 groups, 4 clades ad 16 subtypes [Taken 
from (Medina and García-Sastre 2011)]. 
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engineered H5N1 virus 
Mouse hybridoma 
MAb Chimerization 
Inhibits binding Not tested HA1, RBD 
(140-loop) 
(Hanson et 
al. 2006; Lim 
et al. 2008) 
u-65C6 H5N1 convalescent sera EBV immortalization 







(Hu H. et al. 
2012; Qian et 
al. 2013) 
u-100F4 H5N1 convalescent sera EBV immortalization 
of memory B cells 
Inhibits fusion Homosubtypic Non-RBD, 
HA1 
(Hu H. et al. 
2012; Qian et 
al. 2013) 
o-DPJY01* Attenuated H5N1 virus Mouse hybridoma Inhibits attachment Not tested Undetermined (Ye et al. 
2010) 










(Sun L. et al. 
2009; Cao et 
al. 2012) 
o-9F4 Baculovirus expression of 
recombinant H5 
Mouse hybridoma Inhibits fusion Not tested Non-RBD, 
HA1 
(Oh et al. 
2010) 
HA-7 Recombinant HA1 protein Mouse hybridoma Inhibits fusion Homosubtypic HA1, RBD 
 
(Du et al. 
2013) 





MAb Antigen source Method Mechanism of Action Cross 
protection 
Epitope site Ref 
o-H5M9  Concentrated HA from 
clade 0 virus 
Mouse hybridoma Inhibits attachment 






(Li et al. 
2009; 
Zhu et al. 
2013) 




IgM+ memory B cells 
followed by 
conversion into full 
length IgG1 
Inhibits fusion Heterosubtypic 





FI6 A(H1N1)pdm09 patient/ 
vaccinee sera 
RT-PCR of Ig genes 
from selected plasma 
cells 
 Heterosubtypic 
against all 16 HA 
subtypes 
HA2 (Corti et 
al. 2011) 
Table 1.4 (continued from previous page): Examples of H5 neutralizing MAbs 
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1.10 Rationale of Study Approach and Overview 
 
The overall aim of our research group is to generate MAbs against 
HPAI H5N1 viruses and to assess their potential as therapeutic agents. The 
rarity of cross-neutralizing MAbs in the human immune repertoire and the 
absence of H5N1 viruses or cases in Singapore prompted the use of 
recombinant H5 (rH5) protein and the mouse hybridoma method. Full-length 
rH5 from clade 1 virus, A/chicken/Hatay/2004(H5N1) was expressed in insect 
cells using baculovirus vectors. This system was chosen over bacterial or 
mammalian expression systems as insect cells are capable of post-
translational modifications (unlike bacterial systems) and enable higher 
protein yield (compared to mammalian systems). The immunogenicity and 
safety of recombinant antigen produced by this system has also been 
demonstrated in vaccine formula (Na et al. 2013; Baxter et al. 2011). Full 
length HA protein was chosen as antigen source as it was previously found to 
be superior in eliciting neutralizing antibodies compared to HA1 fragment 
alone (Shen et al. 2008). The purified rH5 was used to challenge naïve mice 
and the spleens were subsequently harvested and fused to myeloma cells to 
produce a library of antibody secreting hybridoma clones. These clones were 
screened for their ability to bind to and neutralize H5 pseudovirus particles.  
Using this method, two mouse MAbs, 9F4 (IgG2b isotype) and 4F3 (IgM 
isotype) were selected for further evaluation in this study based on the 
observation that both MAbs displayed neutralizing activity against multiple 
H5N1 pseudovirus particles (Shen et al. 2009; Oh et al. 2010). 4F3 displayed 
hemagglutination inhibition activity while MAb 9F4 prevented low-pH 
mediated HA conformation change and conferred prophylactic and 
therapeutic protection against lethal infection in mice. Site directed 
mutagenesis assays revealed that the 9F4 epitope is situated away from 
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previously characterized antigenic sites on the HA1 globular head (Oh et al. 
2010), suggesting that MAb 9F4 may be used in synergy with other 
characterized MAbs for combination immunotherapy.  
To our knowledge, most anti-H5 MAbs characterized are of IgG subtype. IgM 
antibodies are associated with preimmune serum or early adaptive immune 
responses and are of relatively broad but low affinity. Binding of these IgM 
antibodies accelerates the development of specific immunity (Corley et al. 
2005; Heymann et al. 1988; Ding et al. 2013) and as such 4F3 could be a 
useful addition to the cocktail of MAbs for combination passive 
immunotherapy. The different mechanisms of inhibition suggest that both 
MAb 9F4 and MAb 4F3 could be used in tandem for passive immunotherapy. 
In this project, the in vitro characterization of MAbs 9F4 and 4F3 is achieved. 
Their ability to bind and neutralize the recently evolved third order H5N1 clade 
is demonstrated and their ability to cross-react with H7 and H9 HA is 
evaluated in Chapter 3.  
9F4 displays potent neutralizing activity across multiple H5 clades and 
subclades, suggesting that it is a good lead antibody. However, the use of 
mouse antibody in humans may lead to rejection or adverse reactions. As 
such, the aim of Chapter 4 of this study was to generate and evaluate two 
chimeric versions of 9F4, designated xi-IgG1-9F4 and xi-IgA1-9F4. We 
demonstrate that xi-IgG1-9F4 retains its binding affinity, mechanism of action 
and neutralizing activity against H5 HA while activity of xi-IgA1-9F4 was 
reduced. We also compared the in vivo immunotoxicity of xi-IgG1-9F4 to 
mouse 9F4.  
Finally, further characterization of the 9F4 epitope is necessary to facilitate its 
future use in combination with other MAbs. Chapter 5 aimed to determine the 
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nature of the 9F4 epitope through bioinformatic analysis and site directed 
mutagenesis. Here, we reveal that 9F4 binds to a conformation dependent 








CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Cell lines and transient transfection 
293FT cells were from Invitrogen. MDCK and HeLa cells were from 
American Type Cell Collection (Manassas, VA, USA). All cell lines were 
cultured at 37 oC in 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum. Growth media for 293FT and 
HeLa cells were further supplemented with non-essential amino acids and 
antibiotics.  
Transient transfection experiments were performed using Lipofectamine™ 
2000 reagent (Invitrogen), according to manufacturer’s instruction. Where 
needed, transfected cells were used directly for immunofluorescence 
experiments or lysed with a lysis buffer containing 150 mM NaCl, 50 mM Tris 
(pH 7.5), 0.5% NP-40, 0.5% deoxycholic acid (sodium), 0.025% SDS, and 1 
mM phenylmethylsulfonyl fluoride for downstream ELISA and Western blot 
analysis.  
2.2 HA expressing plasmids and HA recombinant proteins 
 The H5 expressing plasmids used in this study contained full length 
HA coding sequences from the IAV shown in Table 2. 
Abbreviation Virus Clade ID 
Hatay04 A/chicken/Hatay/2004(H5N1) 1  AJ867074 
VN04 A/Vietnam/1203/2004(H5N1) 1 EF541403 
Indo05 A/Indonesia/5/2005(H5N1) 2.1 EU146622 
India06 A/chicken/India/NIV33487/2006(H5N1) 2.2 EF362418 
DL06 A/duck/Laos/3295/2006(H5N1) 2.3.4  DQ845348 




H7 expressing plasmids contained the full length HA coding sequences from 
Neth H7 [A/Netherlands/219/03(H7N7)] (Genbank accession number: 
AAR02640.1), Shang H7 [A/Shanghai/1/2013(H7N9)] (GISAID ID: 
EPI439486) and Anhui H7 [A/Anhui/1/2013(H7N9)] (GISAID Isolate: 
EPI439507). 
Recombinant HA or HA1 proteins from VN04, India06, Neth H7, Shang H7, 
Anhui H7 and HK H9 [A/Guinea fowl/Hong Kong/WF10/99(H9N2)] (Genbank 
accession number: AY206676) were purchased from Sino Biological Inc. 
2.3 Mouse MAbs 
Mouse MAbs 9F4, 4F3, 8F8 and 8a1 were generated using previously 
established protocol (Oh et al., 2010). MAb 8F8, specific for M1 of Hatay04, 
was used as a negative control IgG antibody. MAb 8a1, specific for S protein 
of severe acute coronavirus (SARS), was used as a negative control IgM 
antibody. IgG and IgM MAbs were purified from ascites fluid or hybridoma 
culture supernatants using HiTrap Protein G columns (GE Healthcare) and 
Pierce IgM purification kit (Thermoscientific), respectively, according to 
manufacturers’ instructions. 
2.4 Cloning and expression of xi-IgG1-9F4 and xi-IgA1-9F4 
Total RNA was extracted from MAb 9F4 hybridoma by using RNeasy 
kit (Qiagen) and used for first strand cDNA synthesis using SuperScript II 
reverse transcriptase (Invitrogen). Variable heavy (VH) and variable light (VL) 
genes were amplified in subsequent PCR using Expand High Fidelity PCR 
(Roche). The Ig-primer set (Novagen) was used for these reactions, 
according to manufacturer’s instruction. PCR products were cloned into 
pCRII-TOPO vector using the TOPO TA cloning kit (Invitrogen) and 
sequencing was performed using BigDye® Terminator v3.1 Cycle 
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Sequencing Kit (Applied Biosystems). Variable regions were then defined 
using the IMGT database (Ehrenmann et al. 2010). 
Variable region specific primers were designed to introduce Mfe1 and Xho1; 
and ApaL1 and Pst1 restriction sites to respectively flank MAb 9F4 VH and 
VL coding sequences by PCR. This enabled the ligation of MAb 9F4 VH to 
human IgG1 heavy chain constant (CH) domain and MAb 9F4 VL to light 
chain kappa constant domain (CL) in a single IgG1 constant region 
expression vector, as previously described. 
Variable region specific primers were designed to introduce EcoRI and NheI; 
and EcoRI and BsiWI restriction sites to respectively flank MAb 9F4 VH and 
VL coding sequences by PCR. This enabled the ligation of MAb 9F4 VH to 
the human IgA1 CH domain within pFUSEss-CHIg-hA1 cloning plasmid and 
the MAb 9F4 VL to the human CL kappa domain within pFUSE2ss-CLIg-hK 
cloning plasmid. Both pFUSEss-CHIg-hA1 and pFUSE2ss-CLIg-hK cloning 
plasmids were purchased from InvivoGen. After successful incorporation of 
MAb 9F4 sequences, the plasmids were co-transfected into 293FT cells as 
described. 
The chimeric constructs were transiently transfected into 293FT cells as 
described. Expression of xi-IgG1-9F4 was checked by immunofluorescence 
analysis while expression of xi-IgA1-9F4 was checked by Western blot. Cell 
culture supernatants containing the respective chimeric MAb were collected 
at 24 h and 72 h post transfection.  xi-IgG1-9F4 and xi-IgA1-9F4 MAbs were 
extracted from the pooled supernatants using a HiTrap protein G and HiTrap 
protein A columns (GE Healthcare) respectively, according to manufacturer’s 




2.5 Immunofluorescence analysis 
293FT or MDCK cells were seeded on coverslips 24 h prior to 
transient transfection with appropriate expression vectors. 24 h post 
transfection, the coverslips were washed twice with 1X phosphate-buffered 
saline (PBS) and cells were fixed with 4% paraformaldehyde (PFA) for 10 min. 
The coverslips were washed and cells were permeabilized with 0.1% Triton-X 
for 10 min, where necessary. The coverslips were washed and blocked with 1% 
BSA in 1XPBS for 30 min and incubated with primary MAbs diluted in 1% 
BSA in 1XPBS for 2 h. After washing to remove unbound MAbs, the cells 
were incubated with Alexa Fluor 488-conjugated goat anti-human IgG or 
Alexa Fluor 488 conjugated goat anti-mouse IgG (Molecular Probes®) for 1 
h. Unbound secondary antibodies were removed by washing and the 
coverslips were mounted onto microscope slides using Fluorosave mounting 
medium (Calbiochem, Merck Chemicals Ltd). Images were obtained using an 
epi-fluorescence microscope (Olympus BX60). 
2.6 Pseudotyped lentiviral particle neutralization assay 
Lentiviral pseudotyped particles (HApp) harbouring the H5N1 HA 
glycoprotein were generated by co-transfection of 293FT cells with an H5N1 
HA expression plasmid and the envelope-defective pNL4.3.Luc.R−E− lentiviral 
vector. HA sequences corresponding to the aforementioned viruses were 
used to generate HApp as previously described (Oh et al. 2010). The 
neuraminidase gene from Hatay04 was also co-transfected to facilitate the 
release of pseudotyped particles from the 293FT cells. The culture 




The pseudotyped particle neutralization assay was performed as previously 
described (Oh et al. 2010). Briefly, MAbs were serially diluted in DMEM and 
mixed with an equal volume of HApp for 1 h. The mixture was used to infect 
MDCK cells, which were seeded in 12-well plates 24h prior to infection. The 
infected MDCK cells were incubated at  37 °C for 72 h and were lysed with 
125 μl of 1X luciferase cell lysis buffer (Promega) per well. 50 μl of the lysate 
was tested for luciferase activity by the addition of 50 μl of luciferase 
substrate (Promega) and luminescence was measured with a luminometer 
(Infinite M200, Tecan). Viral entry, as reflected by the relative light units (RLU), 
was expressed as a percentage relative to the absence of antibody. Each 
experiment was performed in duplicate.  
2.7 Enzyme-linked immunosorbent assay (ELISA) 
The total binding affinity of MAbs for specific test antigen was 
determined by direct ELISA. 96 well ELISA plates were coated with 
recombinant proteins, transfected cell lysates or HApp overnight at 4 oC and 
blocked with 5% milk for 1h. Serially diluted MAbs in 2% milk were added to 
the plates and incubated for 1 h at 37 oC. The plates were washed six times 
with PBS containing 0.05% Tween-20 (PBST) and incubated with 
horseradish-peroxidase-conjugated secondary antibodies (ThermoScientific) 
for 1 h at 37 oC. The plates were washed six times with PBST before the 
reaction was visualized using the substrate 3,3’,5,5’-tetramethylbenzidine 
(TMB) (ThermoScientific) and stopped with 2 M H2SO4. The absorbance at 




2.8 Syncytial inhibition assay  
HeLa cells seeded on glass coverslips were transiently transfected 
with Hatay04-HA as described. The cells were then treated with two test 
concentrations of each MAb for 1 h at 37 oC in 5% CO2, 48 h post transfection. 
Unbound MAbs were removed by washing the cells with 1XPBS prior to 
treatment with low pH buffer for 15 min at 37 oC in 5% CO2. Excess low pH 
buffer was removed by washing and the cells were allowed to recover in 
growth media for 3h at 37 oC in 5% CO2. Cells were stained with CellMask 
Orange (Invitrogen) at 1:5000 dilution and fixed with 4% PFA. Finally, the 
cells were mounted onto glass slides using VectorShield mounting media with 
DAPI (Vector Laboratories) and observed using an epi-fluorescence 
microscope (Olympus BX60). 
2.9 In vivo immunotoxicity assessment of 9F4 MAbs 
 Humanized mice were constructed as previously described (Chen Q. 
et al., 2009). Briefly, NOD-SCIDIl2rg-/- (NSG) mice were humanized at birth 
(less than 48 h old) by irradiation and intracardial injection with CD34+CD133+ 
cells. At 12-weeks of age, humanized mice were injected with 50 µg IL-15 
encoding plasmid and 10 µg Flt3L encoding plasmid by hydrodynamic 
injection to aid in reconstitution of human blood lineage cells, in a total of 1.8-
ml saline within 7s using a 27-gauge needle. After 7 days, mice were 
intravenously injected with 50 µg of mouse 9F4 or xi-IgG1-9F4. After 24 hours, 
whole blood was obtained from mice and the levels of human cytokines in 
serum samples were analysed by ELISA.  
Separately, JcI:ICR mice were injected with 50 µg of mouse 9F4 or xi-IgG1-
9F4. After 24 hours, whole blood was obtained from mice and the levels of 
mouse cytokines in serum samples were analysed by ELISA.  
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2.10 Western Blot 
Western blot was used to analyze protein expression and 9F4 binding 
to reduced and denatured H5 HA. Approximately 24 h post transfection, cells 
were washed twice with phosphate-buffered saline (PBS) and were 
resuspended in 200 µl of lysis buffer as described above (section 2.1). After 
six freeze-thaw cycles, cell debris was removed by centrifugation and the total 
protein concentration in the lysate was determined using the Coomassie Plus 
protein assay reagent from Pierce. 
Equal amounts of proteins were prepared in Laemmli’s SDS buffer, with or 
without boiling for 5 min. Proteins were fractionated by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) under reducing conditions and 
electrotransferred onto a nitrocellulose Hybond-C (Amersham Pharmacia 
Biotech, Uppsala, Sweden) or polyvinylidene difluoride (Millipore, Bedford, 
MA) membrane. The membrane was blocked with 5% nonfat milk in PBS 
containing 0.05% Tween-20 (PBST) for 30 min at room temperature and then 
incubated overnight with the primary antibody at 4°C.  After extensive washes 
with PBST, the membrane was incubated with an appropriate HRP-
conjugated secondary antibody for 1 h at room temperature, followed by 
washing and detection by an enhanced chemiluminescence method (Pierce).  
2.11 Bioinformatic analysis 
Potential epitopes were then detected using two B cell prediction tools 
Bioinformatics predicted antigenic peptides (BPAP) 
(http://imed.med.ucm.es/Tools/antigenic.pl) (Kolaskar and Tongaonkar 1990) 
and BEPro (previously known as PEPITO) 
(http://pepito.proteomics.ics.uci.edu/) (Sweredoski and Baldi 2008). The 
positions of the predicted fragments were visualized on the crystal structure of 
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VN04 (PDB ID: 2FK0) using PyMol (Schrodinger 2010). Fragments containing 
residues within 12Å distance from the previously defined epitope 256I/LVKK259 
were selected for evaluation. 
2.12 Epitope Mapping 
Expression plasmids for the wild-type Hatay04 and mutants were 
generated by polymerase chain reaction (PCR) using Titanium Taq DNA 
polymerase (Clontech Laboratories Inc., Palo Alto, CA). The PCR products 
were cleaved with restriction enzymes BamHI and XhoI and spliced into the 
pXJ3’HA vector. All sequences were confirmed by sequencing performed by 
the core facilities at the Institute of Molecular and Cell Biology, Singapore. 
Wild-type Hatay04 and mutants were transiently transfected into MDCK cells 
and binding was determined by immunofluorescence assay as described 
above. Internal alanine substitution mutant HApp were also generated by co-
transfection with NA and pNL4.3.Luc.R−E− lentiviral vector as described 
above. 
In addition, to determine the minimum H5 fragment required for binding, MAb 
9F4 was screened against a combinatorial antigen library displayed on the 
surface of yeast as previously described (Zuo et al. 2011).  
2.13 Statistical analysis 
The two-tailed Student’s t-test was used to evaluate the statistical 
significance of differences measured from the data sets.  A p value of less 
than 0.05 was considered to be statistically significant. The endpoint titre for 




CHAPTER 3: CHARACTERIZATION OF MAB 9F4 AND 4F3 
 
3.1 MAbs 9F4 and 4F3 bind to heterologous H5N1 viruses 
In 2007, a shift from clade 1 to clade 2.3.4 was reported for human 
H5N1 infections in Vietnam (Le et al. 2008). Clade 2.3.4 viruses have since 
disseminated to Myanmar, Laos, China, Hong Kong and Bangladesh, where 
they have been isolated from humans and domestic birds. In China, clade 
2.3.4 viruses have been responsible for 83% of confirmed human cases of 
H5N1 infection since 2005 and the increased susceptibility to this clade has 
been attributed to the enhanced replication, cytopathology and pro-
inflammatory responses associated with clade 2.3.4 isolates compared to 
other dominant co-circulating clade (2.3.2 and 7) (Sun et al. 2014). 
As clade 2.3.4 viruses retain the previously identified 9F4 epitope site (Figure 
3.1A), we tested the ability of 9F4 to bind to H5 HA from a clade 2.3.4 virus by 
immunofluorescence analysis without cell permeabilization. As shown in 
Figure 3.1B, 9F4 binds to native DL06 transiently expressed on the surface of 
MDCK cells. In contrast, no clear immunofluorescence was seen for 4F3 
against DL06 or any other H5 HA tested, even when these proteins were 
expressed in high transfection efficiency cell line, 293FT (data not shown).  
Next, the neutralizing ability of both MAbs against HApp harboring DL06 was 
also examined. MAb 9F4 inhibited the entry of DL06-HApp in a dose 
dependent manner, whereas the negative control antibody was unable to 
inhibit HApp entry into MDCK cells even at the highest concentration of 10 
μg/ml (Figure 3.1C). The half-maximal inhibitory concentration (IC50) for 
DL06-HApp was about 0.01 μg/ml, similar to clade 1 VN04-HApp as 
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previously reported (Oh et al. 2010) and included in this experiment as a 
positive control.  
Similarly, purified 4F3 was pre-incubated with HApp containing H5 from clade 
1, 2.2 and 2.3.4 viruses. HA from two clade 1 viruses, Hatay04 and VN04, 
were evaluated. Hatay04 and VN04 share 98.94% amino acid similarity and 
bear the same polybasic sequence. As shown in Figure 3.2A, MAb 4F3 
inhibited all H5 HApp in a dose dependent manner, including the more 
recently evolved clade 2.3.4 DL06-HApp. Compared to 9F4, 4F3 is much less 
potent and the IC50 for MAb 4F3 is approximately 10 μg/ml for all H5 HApp 
tested, which is 1000-fold higher than that of MAb 9F4. These findings were 
in good agreement with the preliminary studies (Shen et al. 2009). 
The low potency of 4F3 could be attributed to the low binding affinity of 
preimmune or early immune response IgM antibodies and could explain the 
lack of observable immunofluorescence. Alternatively, the neutralization 
mediated by 4F3 may be due to steric interference rather than direct binding. 
Thus, to evaluate binding, we tested 4F3 binding to H5 HApp in direct ELISA. 
As shown in Figure 3.2B, A450 values for 4F3 is significantly higher for all H5 
HApp compared to the irrelevant IgM control. 4F3 does not bind if the 
pseudovirus particles devoid of HA (pNL43LucR-E- only), indicating that 4F3 








          
 
Figure 3.1: MAb 9F4 binds and neutralizes recently evolved clade 2.3.4 HA. 
A) Sequence alignment of clade 1 and clade 2.3.4 H5. The previously 
identified residues are conserved (inset box). B) 9F4 binds to clade 2.3.4 H5 
transiently expressed on the surface of unpermeabilized MDCK cells. Binding 
was detected using Alexa Fluor
®
 488 Goat anti-Mouse IgG antibodies. C) 
Pre-incubation of DL06-HApp with 9F4 at 37oC for 1 hour prevents entry into 
MDCK cells in a dose dependent manner, with IC95 of 1 μg/ml and IC50 of 
0.01 μg/ml compared to the irrelevant IgG control, which was tested at 10 
μg/ml. HApp entry is expressed as a percentage of RLU in the presence and 
absence of antibodies. Results are normalized against mock infected with 
lentivirus capsid only. VN04-HApp was included in this experiment as a 
positive control. Data points and error bars shown reflect mean and standard 
deviation between duplicate wells. Data shown is representative of three 
































Figure 3.2: MAb 4F3 binds to and neutralizes H5 HApp from multiple clades. 
A) Pre-incubation of H5 HApp from various clades with 4F3 at 37oC for 1 hour 
prevents entry into MDCK cells in a dose dependent manner compared to the 
irrelevant IgM control, which was tested at 10 μg/ml. HApp entry is expressed 
as a percentage of RLU in the presence and absence of antibodies. Results 
are normalized against mock infected with lentivirus capsid only. Data points 
and error bars shown reflect mean and standard deviation between duplicate 
wells. Data shown is representative of three independent experiments. B) 
Equal amounts of HApp (based on p24 titre) were coated onto 96-well plates 
and detected using 5μg/ml 4F3 or the irrelevant IgM control. 9F4 (0.1 μg/ml) 
was included as a positive control. Results are normalized against respective 
MAb values for lentivirus capsid only. Differences in binding between 4F3 and 
IgM control were evaluated by unpaired t-test (*p<0.05, **p<0.01). Data points 
and error bars shown reflect mean and standard deviation between duplicate 
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3.2 MAb 9F4 is homosubtypic while MAb 4F3 is heterosubtypic 
 
 Since it remains impossible to predict the next pandemic subtype or 
strain, the gold standard for passive immunotherapeutic agents against IAV 
are heterosubtypic MAbs. Other than H5, H7 and H9 have been described as 
having the highest pandemic potential by WHO. Thus, we tested the ability of 
9F4 and 4F3 to bind to full length recombinant H7 and H9 HA in direct ELISA. 
For each antibody-HA pair, the upper tail of the Student’s t-distribution of the 
IgG and IgM control antibodies was used to derive cut-off, calculated for 95% 
confidence. The affinity of binding of each test antibody-HA pair is reflected 
by the endpoint titre, which is the antibody concentration that produces a 
A450 reading that is equivalent or lower than the cut-off (Frey et al. 1998).  
9F4 binds to both clade 1 and clade 2.2 H5 proteins comparably and in a 
dose dependent manner (Figure 3.3A) but fails to bind to both H7 (Figure 
3.3B) and H9 (Figure 3.3C). However, 4F3 binds to heterologous H7 HA in 
addition to H5 HA, but not to H9 HA (Figure 3.4). Interestingly, 4F3 binding to 
Neth H7 is stronger than VN04 and India06. 4F3 binding to the various H7 HA 
expressed on the surface of HApp was also detectable (Figure 3.5A) and was 
functional in neutralizing H7 HApp with an IC50 of 10 μg/ml (Figure 3.5B).  
Although other HA subtypes were not tested, the results suggest that 9F4 is 







       
 
Figure 3.3: 9F4 is a homosubtypic MAb. 96-well ELISA plates were coated 
with 0.1μg/well of recombinant HA proteins from A) VN04 (clade 1) and India 
H5 (clade 2.2). Absorbance was obtained within 5 min post addition of TMB 
substrate. Wells coated with 1μg/well of B) Netherlands H7 and C) HK H9 did 
not give absorbance readings over the cut-off values although TMB substrate 
contact time was extended beyond 30 min. Data points and error bars shown 
reflect mean and standard deviation between duplicate wells. Data shown is 
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Figure 3.4: 4F3 is a heterosubtypic MAb and binds to recombinant H5 and 
H7 proteins. 96-well ELISA plates were coated with 0.1μg/well of recombinant 
HA proteins from A) VN04 (clade 1), B) India H5 (clade 2.2), C) Netherlands 
H7, D) Anhui H7or E) Shanghai H7. F) Wells were coated with 1μg/well of HK 
H9. Data points and error bars shown reflect mean and standard deviation 


















































































































Figure 3.5:  4F3 binds to and neutralizes H5 and H7 HApp. A) Equal amounts 
of HApp (based on p24 titre) expressing the various HA were coated onto 96-
well plates and detected using 5μg/ml 4F3. Positive control antibodies for H5 
and H7 HApp were MAb 9F4 and Rb anti-H7N9.The experiment was 
performed in duplicates and results are normalized against mock supernatant. 
Data shown is representative of three independent experiments. B) Pre-
incubation of various H7 HApp with 4F3 at 37oC for 1 hour prevents entry into 
MDCK cells in a dose dependent manner compared to the irrelevant IgM 
control, which was tested at 10 μg/ml. HApp entry is expressed as a 
percentage of RLU in the presence and absence of antibodies. Results are 
normalized against mock infected with lentivirus capsid only. Data points and 
error bars shown reflect mean and standard deviation between duplicate 






















































3.3 MAbs 9F4 and 4F3 bind to HA1  
HA MAbs can be classified as anti-HA1 or anti-HA2. As the previously 
identified epitope of 9F4 is located in the HA1 domain and because 4F3 
displays HAI activity, we compared the binding affinity of both MAbs to full 
length HA compared to HA1 only. As shown in Figure 3.6A, 9F4 bound both 
full length and HA1 recombinant proteins derived from India06, however, 
binding to full length HA was stronger as indicated by the higher A450 values 
at all concentrations tested. The endpoint titre for full-length India06 HA is 10-
fold lower than that of India06 HA1 protein. This indicates that although HA1 
is sufficient for 9F4 binding, HA2 residues contribute to overall strength of 
binding. In contrast, 4F3 binding to HA and HA1 proteins were similar for both 
India06 (Figure 3.6B) and Anhui H7 (Figure 3.6C) at all concentrations tested, 
with endpoint titres of 0.625 μg/ml. This indicates that HA1 alone mediates 
4F3 binding, with little or no contribution by HA2. Consistent with previous 
data, the lower endpoint titre observed for 9F4 compared to 4F3 also reflects 










Figure 3.6: HA1 is sufficient for binding by 9F4 and 4F3. ELISA plates were 
coated with full length or HA1 only recombinant HA proteins at equimolar 
concentrations. A) 9F4 binding to full length India06-HA is stronger than 
India06-HA1 only. Background absorbance due to the IgG control MAb was 
used to derive cut-off. 4F3 shows comparable binding affinity to (B) full length 
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Anhui H7-HA1 only. Background absorbance due to the IgM control MAb was 
used to derive cut-off for 4F3. 
 
3.4 Discussion 
Although human transmission of HPAI H5N1 remains an infrequent 
event, the high case fatality rate, ongoing evolution and potential risk of 
human adaptation underscore the need for the development of readily 
available prophylactic or therapeutic agents. MAbs 9F4 and 4F3 were 
selected for further characterization as both MAbs were able to prevent the 
entry of H5 HApp from multiple clades. In Singapore, H5N1 viruses are 
classified as Schedule I agents under the Biological Agents and Toxins Act 
(BATA), requiring stringent import, possession and production permits and 
BSL3 facilities. HApp contain the firefly luciferase reporter gene and permits 
the sensitive quantification of pseudovirus entry into host cells, which have 
been shown to display similar entry characteristics and neutralization titres as 
live IAV (Garcia and Lai 2011). Thus, the use of HApp instead of H5N1 
viruses enabled the study of virus entry within the confines of a BSL2 
laboratory.  
Using this system, the ability of 9F4 and 4F3 to neutralize the more recently 
evolved third-order clade 2.3.4 representative virus was shown. Despite the 
lack of observable 4F3 binding to HA transiently expressed on the surface of 
MDCK or 293FT cells, both 9F4 and 4F3 bound to and neutralized native and 
mature forms of H5 HA on the surface of HApp as well as solubilized mature 
HA recombinant proteins. The differences in binding profiles of both 9F4 and 
4F3 (summarized in Table 3.4) may be attributed to differences in binding 
potency. 9F4 binds to and neutralizes H5 HA in the nanogram scale while 
4F3 is only active in the microgram scale. While the low transfection efficiency 
of liposome based transient transfection in MDCK cells may account for the 
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lack of detectable immunofluorescence for 4F3, there is also a surprising lack 
of clear immunofluorescence in transiently transfected 293FT cells, which are 
highly responsive to liposome based transfection (Maurisse et al. 2010). One 
possible explanation is that the pentameric structure of IgM requires antigen 
to be spatially close together for maximum avidity and the concentration of 
HA proteins within individual HApp could be more permissive to 4F3 binding 
compared to HA proteins diffused on the surface of transfected cells. The 
stronger binding affinity towards Neth H7 compared to H5 HA in all assays 
also suggests that the epitope site may be more exposed in Neth H7 
compared to H5. Whether this increased affinity translates to increased 
neutralization ability remains difficult to assess as it is unknown if H5 and H7 
incorporates within HApp to similar extends or if H7 HApp transduces MDCK 
cells as effectively as H5 HApp. 
 9F4 4F3 






Does not bind 





HApp neutralization (IC50) 0.01 μg/ml 10 μg/ml 
Binding  site HA1 
(HA2 may contribute) 
HA1 only 
Table 3.1: Summary of findings for MAbs 9F4 and 4F3 
 
The ability of 4F3 to bind multiple H5 clades and to two H7 subtypes 
associated with zoonosis in humans is of interest. Like the 2013 H7N9 virus 
(discussed in 1.5.2), the 2003 H7N7 virus that infected humans in 
Netherlands is also a reassortant virus (Fouchier et al. 2004) and both belong 
to the H7 Eurasian lineage (Lebarbenchon and Stallknecht 2011; Liu et al. 
2013). All H7 HA share high sequence identity with one another but not with 
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H5, suggesting that the epitope may be more accessible among H7 HA 
compared to H5 HA. Interestingly, 4F3 binds to and neutralizes H7 HA but not 
H9, although the sequence identity between H9 and H5 HA is higher than that 
between H5 and H7 (Table 3.2). As mentioned in Chapter 1.9, most 
characterized heterosubtypic IAV MAbs seldom bind across HA groups and 
are generally confined to one of the two HA groups. H5 and H9 are group 1 
HA while H7 is a group 2 HA. Further studies focusing on characterizing the 
4F3 epitope could reveal useful information on cross-protective epitopes for 
vaccine design (discussed in Chapter 6).  
  VN04 Hatay04 Indo05 India06 DL06 Neth H7 Anhui H7 Shang H7 HK H9 
VN04 100 98.55 95.66 95.38  94.19  33.82  33.33  33.33  41.72  
Hatay04 98.94 100 95.38  95.09  93.9  33.24 32.74 32.74 42.31 
Indo05 96.65 96.3 100 95.38 94.77 32.66 32.45 32.45 42.01 
India06 96.83 96.48 96.48 100 94.77 33.53 33.33 33.33 41.72 
DL06 96.3 95.95 96.48 96.65 100 34.59 33.63 33.63 41.72 
Neth H7 40.57 40.75 40.39 40.93 41.46 100 94.69  95.28 34.91 
Anhui H7 40.89 40.36 40.18 40.71 41.07 96.07 100 97.94 34.62 
Shang H7 40.54 40 40 40.36 40.71 96.07 98.39 100 34.02 
HK H9 50 50.18 50.71 50.18 50.18 42.32 41.79 41.43 100 
Table 3.2: Sequence identity of HA used in this study. White boxes: % 
identity of full length HA. Blue boxes: % identity of HA1 
 
The broad binding profile and low potency of 4F3 suggests that it could be an 
early-immune antibody, selected prior to affinity maturation or alternatively, a 
naturally occurring preimmune antibody, generated in a T cell independent 
manner. As discussed in Chapter 1, B cell activation is largely T cell 
dependent, enabling somatic hypermutation and isotype switching. In addition 
to T cell dependent B cell activation, T cell independent B cell activation can 
occur. Type I T cell independent B cell activation occur when B cells bind 
antigen via natural or memory antibodies attached by Fc (fragment, 
crystallizable) receptors (FcR). These B cells become activated after 
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receiving secondary stimulation by antigen-bound TLR and are restricted to 
IgM production specific to the antigen bound by TLR. Type II T cell 
independent B cell activation occurs when antigen cross-link natural or 
memory IgM bound to B cells, leading to their direct activation in the absence 
of T cell activation. T cell independent antibody production is largely limited to 
IgM and do not undergo affinity maturation, explaining the poor antigen 
affinity associated with such MAbs.  
The therapeutic benefits of IgM in passive immunotherapy are debatable. IgM 
neutralizing MAbs were not effective in protecting mice against IAV infection 
when introduced by intraperitoneal injection, presumably due to poor tissue 
accessibility by the large IgM molecule (Palladino et al. 1995). However, mice 
deficient in IgM, but not other antibody isotypes, show increased pulmonary 
IAV titres (Kopf et al. 2002). In addition, poor affinity IgM antibodies are 
known to act as natural adjuvants (Link et al. 2012; Heyman et al. 1988) and 
could contribute to the rescue of endogenous adaptive immune responses if 
given as part of the passive immunoprophylaxis regime. IgM is required to 
sequester pathogens to secondary lymphoid tissues, thereby preventing 
extrapulmonary dissemination into vital organs (Ochsenbein et al. 1999), a 
feature that has been described in critical H5N1 disease (de Jong et al. 2006). 
The ability of IgM to concentrate antigen to lymphoid tissues could be useful 
since studies of lethal H5N1 infection in mice and ferret models suggest that 
development of robust adaptive anti-H5N1 immune responses are unlikely as 
circulating lymphocytes are depleted and apoptosis of leukocytes within the 
germinal centres occurs early on during infection (Tumpey et al. 2000). In 
addition, mice deficient in IgM FcR (FcμR) have impaired germinal centre 
formation and humoral responses (Ouchida et al. 2012), highlighting the 
importance of IgM in linking the innate and adaptive arms of immunity to 
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specific antigen.  Finally, IgM potently activates complement leading to lysis 
of infected cell. Binding of a single IgM molecule to antigen is sufficient for 
complement activation, while cross-linking of at least two IgG antibodies is 
required for complement fixation (Borsos and Rapp 1965). Complement 
deposition onto the surface of IAV particles mediated by IgM also contributes 
to IAV aggregation and neutralization (Jayasekera et al. 2007). However, 
complement fixation also activates cytokine production and may aggravate 
hypercytokinaemia seen in severe influenza infections of both H5N1 and 
H7N9. Thus, in vivo studies of 4F3 are needed to evaluate their suitability as 
immunotherapeutic agents. 
Unlike 4F3, 9F4 provided almost complete neutralization of H5 HApp at 1 
μg/ml. The high potency, novel epitope site and ability and ability to bind 
multiple H5N1 clades (Oh et al. 2010), makes it an attractive candidate for 
use in synergy with other well characterized MAbs that bind away from the 
9F4 epitope. To reduce the potential for rejection in humans, the 
chimerization of 9F4 was achieved and this is discussed in the next chapter. 
Additionally, isotype switching of 9F4 to IgA1 is also discussed due to the role 






CHAPTER 4: CHIMERIZATION OF MAB 9F41 
4.1 Construction of mouse- human IgG1 and IgA1 9F4 MAbs 
As discussed in the Chapter 3, the ability of MAb 9F4 to potently 
neutralize multiple circulating H5N1 clades makes it an attractive lead 
antibody for passive immunotherapy. To minimize potential human anti 
mouse antibody (HAMA) reaction against MAb 9F4, a mouse-human chimeric 
form of MAb 9F4, designated xi-IgG1-9F4, was generated. The VH and VL 
chains of MAb 9F4 were obtained from the messenger RNA of the hybridoma 
by using PCR method (Appendix) and were fused to gene fragments 
encoding for CH chain of human IgG1 and CL of the kappa chain respectively. 
The resultant construct was transiently transfected into 293FT cells and the 
expression of xi-IgG1-9F4 in 293FT cells was checked by 
immunofluorescence assay. Positive immunofluorescence only in the 
presence of Alexa Fluor 488-conjugated goat anti-human IgG confirmed the 
chimerization of MAb 9F4. No immunofluorescence was detected in the 
presence of Alexa Fluor 488-conjugated goat anti-mouse IgG, indicating 
successful replacement of heavy and light chains to human forms (Figure 
4.1A).  
Similarly, a chimeric IgA1 form of MAb 9F4 was generated by fusing 9F4 VH 
and VL to the coding regions for CH chain of human IgA1 and CL of the kappa 
chain, respectively. 293FT cells were used as the producer cells and 
expression of xi-IgA1-9F4 was detected using anti-human-IgA-HRP 
conjugated antibody in western blot analysis (Figure 4.1B). 
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Figure 4.1: Successful expression of two mouse-human chimeric forms of 
MAb 9F4 in mammalian cells. 
(A) Expression of xi-IgG1-9F4 was checked by immunofluorescence using 
Alexa Fluor 488-conjugated goat anti-human IgG and goat anti-mouse IgG 
antibodies. Original magnification x10. (B) Expression of xi-IgA1-9F4 was 
checked by western blot using anti-human-IgA-HRP antibody. 
 
4.2 xi-IgG1-9F4 retains a comparable level of activity  
Transfected 293FT culture supernatants were collected at 48 and 72 
hours post transfection and passed through HiTrap Protein G columns. The 
purity of xi-IgG1-9F4 was verified using SDS-PAGE and Coomassie staining. 
Purified xi-IgG1-9F4 retained the ability to bind to native H5 HA from multiple 









(Figure 4.2A). No immunofluorescence was observed when fluorophore-
conjugated- anti-mouse IgG was used as a secondary antibody (data not 
shown). The results indicate that conversion to xi-IgG1 was successful and 
does not impede cross-clade binding.   
Next the relative ability of xi-IgG1-9F4 to neutralize HApp compared to 
parental mouse 9F4 was determined as described in Chapter 3. Both mouse 
and xi-IgG1-9F4 inhibited the entry of HApp containing the HA of various H5 
clades in a dose dependent manner. The negative control antibody was 
unable to inhibit entry of all HApp tested, even when used at 10 μg/ml (Figure 
4.2B-E). Neutralization of Indo05-HApp and India06-HApp mediated by 
mouse and xi-IgG1-9F4 was similar at all MAb concentrations tested. xi-IgG1-
9F4 only differed in its ability to neutralize VN04-HApp and DL06-HApp entry 
at the highest concentration tested (1 μg/ml), where a 10% reduction in the 
inhibition was observed for xi-IgG1-9F4 compared to 9F4. Nevertheless, xi-
IgG1-9F4 retains high neutralizing potency similar to mouse 9F4, with an IC50 



































































    
 
 
Figure 4.2 (continued from previous page): xi-IgG1-9F4 retains its ability to 
bind to multiple H5 clades A) Binding of xi-IgG1-9F4 to various H5 expressed 
on the surface of MDCK cells was detected using fluorophore conjugated 
goat anti-human-IgG.  B-E) Different concentrations of 9F4 and xi-IgG1-9F4 
were pre-incubated with HApp containing H5 from B) VN04, C) Indo05, D) 
India06 and E) DL06 at 37oC for 1 hour. The irrelevant IgG control was tested 
at 10 μg/ml. HApp entry is expressed as a percentage of RLU in the presence 
and absence of antibodies. Results are normalized against mock infected with 
lentivirus capsid only. Each experiment was repeated three times, each in 
duplicates. Each histogram and error bar represents the mean and SD of all 
























































4.3 xi-IgA1-9F4 exhibits decreased activity 
Next, xi-IgA1-9F4 was purified using HiTrap protein A columns and 
tested in HApp neutralization assay. Although VN04-HApp neutralization 
mediated by xi-IgA1-9F4 occurred in a dose dependent manner, a significant 
reduction was observed at all MAb concentrations tested. xi-IgA1-9F4 was 
unable to completely neutralize HApp entry even at 10 μg/ml and has an IC50 
of 0.1 μg/ml, which is 10 fold higher than the parental 9F4 (Figure 4.3A). 
To account for the reduction in neutralization, comparative ELISA using total 
cell lysates from 293FT cells transiently expressing VN04, Hatay04 and DL06 
was performed. These cell lysates contain all expressed forms of HA 
(precursor HA0 and mature disulfide-linked HA1-HA2 on cell surface) and 
were therefore suitable for assessing total binding affinity. As shown in Figure 
4.3B, binding by xi-IgA1-9F4 was significantly decreased compared to both xi-
IgG1-9F4 and mouse 9F4, which bound comparably to all H5 HA at all 
concentrations tested. The endpoint titre for xi-IgA1-9F4 was 1.25 μg/ml for all 
H5 HA tested, whereas xi-IgG1-9F4 and mouse 9F4 exhibited strong binding 
at this concentration. 




       
 

































































































Figure 4.3 (continued from previous page): Conversion to xi-IgA1 diminishes 
9F4 activity. (A) Pre-incubation of VN-04 HApp at 37oC for 1 hour with xi-IgA1-
9F4 showed a diminished ability to neutralize HApp entry into MDCK cells 
compared to mouse 9F4. The irrelevant IgG control was tested at 10 μg/ml. 
HApp entry is expressed as a percentage of RLU in the presence and 
absence of antibodies. Results are normalized against mock infected with 
lentivirus capsid only. Each experiment was repeated three times, each in 
duplicates. Each histogram and error bar represents the mean and SD of all 
three experiments. Differences in binding between xi-IgA1-9F4 and mouse 
9F4 were evaluated by unpaired t-test (*p<0.05, **p<0.01). (B–D) 
Comparative ELISA as performed to measure the binding of different forms of 
MAb 9F4 to fixed amount of cell lysates obtained from cells transfected with a 
cDNA construct expressing various H5 HA. All readings are normalized 
against cell lysates from 293FT cells transfected with empty vector alone. The 
experiments were repeated three times. Each point shows the mean of the 
values from all data. Error bars, standard deviations. The cut-off level was 
determined using an irrelevant control mouse MAb. Differences in binding by 






































4.4 xi-IgG1-9F4 retains ability to inhibit fusion at low pH  
Since xi-IgG1-9F4 showed comparable binding and neutralizing activity as 
mouse-9F4, the ability of xi-IgG1-9F4 to inhibit fusion was determined by 
syncytial inhibition assay. It was previously suggested that MAb 9F4 inhibits 
fusion of viral and host endosomal membranes as MAb 9F4 did not show 
hemagglutination inhibition activity and was able to prevent low pH mediated 
HA conformational change (Oh et al. 2010). Here, HeLa cells expressing 
Hatay04 were subjected to low pH treatment, allowing HA to adopt the 
conformational change needed for mediating fusion of cell membranes. The 
resultant syncytia formation was analyzed by means of immunofluorescence 
staining. No syncytial formation was observed for untransfected cells (Figure 
4.4, first column), while large multinucleated syncytia bodies were observed 
for HeLa cells expressing Hatay04-HA in the absence of antibodies (Figure 
4.4 second column). Pre-incubation of transfected cells with the irrelevant IgG 
mouse antibody prior to low pH treatment did not prevent syncytia formation 
(Figure 4.4 third column). In contrast, the pre-incubation of transfected cells 
with either mouse-9F4 and xi-IgG1-9F4 reduced the amount and size of 
syncytia formation at a MAb concentration of 10 µg/ml and this reduction was 
more pronounced at 50 µg/ml (Figure 4.4 fourth and fifth column). The results 





Figure 4.4: Both mouse- and xi-IgG1-9F4 comparably inhibit HA mediated fusion at low pH.    
HeLa cells were transiently transfected with a cDNA construct expressing Hatay04-HA and then incubated with mouse-9F4 or xi-
IgG1-9F4 at two different concentrations. Control cells were not treated or incubated with control mouse-8F8 antibody. 
Subsequently, the unbound MAbs were removed by washing the cells with 1XPBS prior to treatment with low pH buffer and 
followed by recovery, fixation and staining.  Plasma membrane is stained orange (CellMask Orange) and nucleus is stained blue 
(DAPI). Pictures shown are representative of 20 fields and 3 independent experiments. The top two panels were taken at original 
magnification x10 while the bottom panel was taken at original magnification x40.  
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4.5 Both 9F4 and xi-IgG1-9F4 do not cause immunotoxicity in vivo 
Antibodies of the IgG isotype are the most abundant in mice and 
humans. Their long serum half life and natural roles in primary and secondary 
responses to infection makes them an attractive form for use in passive 
immunotherapy. However, unexpected off-target antibody binding could 
trigger inflammation. Furthermore, IgG mediate pro- and anti-inflammatory 
effector functions via binding of their Fc portions with Fcγ receptors (FcγR) 
that are broadly expressed on immune cells. Antibody-mediated inflammation 
could prove detrimental for immunotherapy, particularly when disease 
severity of H5N1 is correlated with an exacerbated inflammatory response. 
To test if 9F4 MAbs are associated with such potential immunotoxic effects, 
the MAbs were injected into humanized mice, developed by the adoptive 
transfer of human hematopoietic stem cells followed by the reconstitution of 
human blood lineage cells in NSG mice (lacking mice T, B and NK cells) 
(Chen Q. et al. 2009). JcI:ICR were included in this experiment for 
comparison as a model of non-humanized mice. JcI:ICR was chosen as it is a 
genetic precursor of the NOD mouse (Ikegami and Makino 2005). Figure 4.5 
shows the distribution of pro-inflammatory cytokine responses of mice 
injected with either 9F4 or xi-IgG1-9F4. For each mouse, the IFNγ, IL-6 and 
IL-8/ MIP-2 concentrations were measured by capture ELISA as these 
cytokines are indicative of a classically activated macrophage response. A 
significant elevation of cytokines (p<0.01 for all cytokines tested) was 
observed in xi-IgG1-9F4 treated JcI:ICR mice compared to 9F4 treated 
JcI:ICR mice (Figure 4.5). This could be due to anti-human-antibody-like 
reaction in mice. Nevertheless, the cytokine levels for both MAbs remained 
low in all humanized and untreated JcI:ICR mice compared to mouse models 
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of cytokine storm (Shi X. et al. 2013), suggesting that these MAbs alone do 
not cause any immunotoxic effects.  
 
Figure 4.5: 9F4 MAbs are not associated with immunotoxicity in vivo.  
A) Cytokine profiles of humanized mice treated with xi-IgG1-9F4 (n=9) or 9F4 
(n=7). NSG mice transplanted with human hematopoietic stem cells were 
treated with 50 µg IL-15 encoding plasmid and 10 µg Flt3L encoding plasmid 
by hydrodynamic injection to aid in reconstitution of human blood lineage 
cells. After 7 days, mice were injected with 100 µg of 9F4 or with xi-IgG1-9F4. 
After 24 hours, whole blood was obtained from mice and the levels of human 
cytokines in serum samples were analysed by ELISA. B) Cytokine profiles of 
JcI:ICR mice treated with xi-IgG1-9F4 (n=5) and 9F4 (n=5) were included in 
this experiment for comparison. Histograms and error bars reflect mean and 






Although fully human anti-H5 antibodies have been described the generation 
of such antibodies typically require H5N1 convalescent donors as cross-
protective antibodies obtained from patients previously immunized with other 
subtypes of influenza are rare (Corti et al. 2011). As such mouse hybridoma 
technology continues to be a popular method for in vitro generation of pre-
pandemic MAbs. A common solution to reducing potential HAMA response is 
to make mouse-human chimeric constructs, consisting of the original mouse 
variable antibody domains fused to human constant domains. The resultant 
xi- MAb should retain the binding properties of the original mouse MAb, but 
with reduced immunotoxicity. Of the 36 currently approved therapeutic MAbs 
available in the market, 6 are mouse-human chimeric and an additional 5 
chimeric MAbs are currently undergoing clinical trials (Strohl 2014), indicating 
that these MAb forms can be tolerated in humans. As the outcome of passive 
immunotherapy could be dependent on the efficacy by which therapeutic 
MAbs reach the sites of viral replication, mouse IgG2b 9F4 was converted into 
two chimeric and isotype variants: xi-IgG1-9F4 and xi-IgA1-9F4.  
Antibodies of the IgG isotype are the most abundant in mice and humans. 
Their long serum half-life, ease of application and natural roles in primary and 
secondary responses to infection make them an attractive form for use in 
passive immunotherapy. Mice deficient of endogenous T and B cell 
responses survived lethal IAV infection when given individual neutralizing 
MAbs of IgG1, IgG2a, IgG2b and IgG3 isotypes, attesting to the sufficiency of 
passively transfused IgG in mediated protection (Palladino et al. 1995). In this 
chapter the ability of xi-IgG1-9F4 to retain binding affinity and neutralization 
potency to multiple clades of H5 HA was demonstrated. The ability to prevent 
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membrane fusion at low pH was also comparable to mouse 9F4. Thus, xi-
IgG1-9F4 is a suitable alternative to mouse 9F4 for use in humans. As 
discussed in Chapter 1, most neutralizing IAV MAbs described are of IgG 
isotype and their protective ability in mice and ferret models are widely 
recognized. However, the degree of protection observed by intravenously 
administered IgG MAbs could be due to the disseminated nature of HPAI 
H5N1 replication in murine infection model. Although H5N1 can cause 
disseminated infection in humans, the lungs remain the primary site of viral 
infection (Uiprasertkul et al. 2005; Sirinonthanawech et al. 2011). As such, 
very high doses of IgG must be introduced intravenously in order for sufficient 
levels of IgG to transudate from the plasma to the lungs to mediate protection 
(Renegar et al. 2004). To improve recovery of IgG at the lungs, vectored 
delivery of whole antibody gene directly at the nasopharyngeal mucosa has 
been explored as a practical strategy. This approach has yielded encouraging 
results in both mice and ferret models of H5N1 and H7N9 infection (Limberis 
et al. 2013). Most importantly, vectored antibody delivery enabled antibody 
expression to last for up to 100 days (Limberis et al. 2013) suggesting that 
this could be a feasible prophylactic approach prior to the availability of 
vaccines in an outbreak setting. 
In this study, xi-IgA1-9F4 antibody was also generated for several reasons. 
Firstly, IgA1 is naturally predominant in the nasal mucosa during influenza 
infection (Burlington et al. 1983) and the presence of specific secretory IgA in 
the upper respiratory tract is associated with resistance to severe respiratory 
disease (Weltzin and Monath 1999). Secondly, IgA is potentially 
advantageous over IgG as it does not fix complement via the classical 
pathway and is therefore thought to be less pro-inflammatory than IgG MAbs 
(Woof and Russell 2011). This characteristic could be of importance in severe 
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influenza diseases where poor clinical outcome correlates with uncontrolled 
and excessive inflammation (discussed in Chapter 1). Thirdly, IgA1 permits 
two routes of administration. Intranasal administration allows IgA to neutralize 
influenza directly at the primary site of infection (Ye et al. 2010). Intranasal 
IgA but not IgG also prevents transmission of IAV in guinea pig model 
(Seibert et al. 2013). Alternatively, dimeric IgA can be generated for systemic 
administration, allowing IgA to bind to polymeric Ig Receptors (pIgR) located 
at the basal membrane of epithelial cells for transepithelial transport to the 
respiratory mucosa (Tamura et al. 2005). Dimerization of IgA also increases 
its ability for antigen agglutination and polymeric IgA versions of IgG 
antibodies can improve reactivity to specific antigen for other diseases 
affecting the mucosa (Liu et al. 2003). Despite its importance in the 
respiratory mucosa, only one anti-H5 IgA MAb, generated using mouse 
hybridoma has been reported (Ye et al. 2010). Unfortunately, xi-IgA1-9F4 
showed substantial reduction in binding and a 10-fold increase in the IC50 
value for HApp neutralization assay. Since all three forms of 9F4 MAb have 
the same variable domains, the reduction in binding and neutralization ability 
could be attributed to the differences in the constant domains. As mentioned, 
the variable regions are generally sufficient for binding, however, for some 
MAbs, constant binding regions may also contribute through steric hindrances 
and inducing conformational changes in the targeted antigen (Nason et al. 
2001). Another possible explanation is that fusion to the IgA1 Fc domain 
interferes with the structure of the 9F4 variable domain. Future structural 
studies of xi-IgA1-9F4 and xi-IgG1-9F4 may provide insights into how to 
restore xi-IgA1-9F4 activity. 
In addition to neutralization, MAbs interact with components of the host 
immune system primarily via their Fc receptors. Thus, their immune 
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modulatory properties may lead to adverse immunotoxicity events such as 
immunostimulation and hypersensitivity. Immunostimulation can occur when 
acute cytokine release causes clinical symptoms similar to the cytokine storm 
seen in severe influenza disease. In extreme cases, acute cytokine release 
occurs within a few hours of MAb infusion and cause potentially lethal 
cardiovascular disturbances. Although such cases are due mainly to MAbs 
targeting host cell factors rather than pathogen targets (Wing 2008), any 
unexpected off-target reactions remains a risk for adverse reactions. Current 
preclinical studies are inadequate in identifying these adverse events, 
primarily due to the lack of effective animal models. This inadequacy was 
highlighted when one MAb caused disease in healthy volunteers during 
phase 1 clinical trial (Suntharalingam et al. 2006).  
Over the past decade, humanized mice, bearing components of the human 
immune system, have been touted as suitable models for the in vivo study of 
immune response to various pathogens, and for preclinical evaluation of 
vaccines or drugs (Legrand et al. 2009). These small animal models permit 
the experimentation on human systems without putting individuals at risk. 
Experimentation with mice is also more ethically acceptable compared to 
large primate models. SCID mice are popular for the generation of such 
animal models as these mice lack of T and B cell functions, enabling human 
graft or transplant without rejection. Initially, these mice were humanized by 
the simple transfusion of human peripheral blood lymphocytes (hu-PBL-
SCID). Such models have been used to study neutralizing antibodies, Fc 
function and immune escape against blood borne infections such as human 
immunodeficiency virus (HIV) (Andrus et al. 1998; Gauduin et al. 1998; Safrit 
et al. 1993). However, engraftment of human lymphocytes to the peripheral 
organs was poor and the model did not show consistency in its ability to 
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mount robust human immune responses. Engraftment was improved by 
crossing SCID mice with NOD/Lt mice and these observations were attributed 
to reduced macrophage functions, NK activity and complement activation in 
the resultant NOD-SCID mice in addition to abrogated adaptive immunity 
(Greiner et al. 1995). In more recent humanized mice, such as the NSG 
model used in this study, the common gamma chain (IL2Rγ) is also knocked 
out. These mice are transplanted with human stem cells. This completely 
ablates mouse NK cells and demonstrates superiority in engraftment 
efficiency and ability to differentiate into multiple blood lineages, although 
reconstitution of lymphoid lineages is superior (Shultz et al. 2005). 
Hydrodynamic tail vein injection with vectored human cytokines genes IL-15 
and FL further improves the reconstitution of human myeloid lineage cells 
such as macrophages, NK cells and dendritic cells (Chen Q. et al. 2009) and 
was used in this study.  
As the main pro-inflammatory cytokines associated with cytokine storm 
includes IFNγ, IL-6, and IL-8 (Descotes and Vial 2007) we evaluated the 
levels of these cytokines after passive transfer of the 9F4 MAbs. Surprisingly, 
both xi-IgG1-9F4 and mouse 9F4 had an unremarkable effect on cytokine 
activation in both humanized and normal mice, suggesting that both versions 
of 9F4 have low immunotoxicity profiles. However, it is important to note that 
these MAbs were tested in the absence of antigen, the responses only reflect 
cytokine induction via the FcγRIA, which binds monomeric IgG1. Other FcRs 
bind IgG in its immune-complexed form and it is necessary to perform further 
studies in the context of infection.   
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CHAPTER 5: EPITOPE MAPPING OF MAB 9F4 
 
5.1 The previously characterized 9F4 epitope is insufficient for 
binding 
 
To allow comparison to other anti-H5 MAbs, the mature H5 numbering 
convention is adopted in this chapter. Previously, an epitope 256I/LVKK259 
within the HA1 subunit  was found to be essential for the interaction with MAb 
9F4 because full-length HA lacking this epitope could not bind MAb 9F4 (Oh 
et al. 2010). However, in ELISA analysis (Figure 5.1A), MAb 9F4 failed to 
react with linear peptide 255KIVKKGDSTIM265 bearing 256I/LVKK259, although it 
reacted strongly with native recombinant HA1 protein, which contains the 
peptide sequence, indicating that 256I/LVKK259 is insufficient for binding. Hence, 
the ability of MAb 9F4 to bind to various transitional states of HA in western 
blot analysis was next examined. 293FT cells were transiently transfected 
with Hatay04, VN04 and DL06 and the expression levels were verified using 
a rabbit polyclonal antibody raised against the N terminus of HA (Figure 5.1B 
left panel). To compare the ability of MAb 9F4 to bind completely denatured 
and reduced HA versus partially denatured and reduced HA, western blot 
analysis was conducted under reducing conditions but with or without boiling. 
The results clearly show that MAb 9F4 binding to completely reduced and 
denatured H5 was diminished when samples were boiled (Figure 5.1B middle 
panel) while binding to the various H5 HA was detectable when the sample 
was not boiled (Figure 5.1B right panel). Taken together, the results imply 
that MAb 9F4 has a binding preference towards native conformations of HA 








Figure 5.1: 9F4 recognizes a conformation dependent epitope  
A) ELISA analysis of 9F4 to recombinant H5 HA1 protein and 
255KIVKKGDSTIM265 recombinant peptide. Histograms and error bars reflect 
mean and SD of duplicate experiment. **p<0.001. B) Lysates of 293FT cells 
expressing H5 HA of different clades were used in western blot analysis. 9F4 
binding to completely reduced and denatured H5 (top middle panel) was 
compared to partially reduced or denatured H5 (top right panel). Expression 
levels of H5 proteins were checked using a rabbit polyclonal antibody raised 
against the N terminus of HA (top left panel) and levels of endogenous actin 






5.2 In silico prediction of antigenic fragments 
The final 9F4 epitope is likely a structural epitope since linearization of 
H5 in western blot analysis results in the loss of binding. Structural epitopes 
comprise of scattered linear fragments within the primary sequence of a 
protein that come together to form the antibody-binding site in eventual 
protein structure (Sivalingam and Shepherd 2012). To guide experimental 
epitope mapping, two epitope prediction methods were used to identify 
potential antigenic fragments within VN04. The first method, BPAP, scores 
potential fragments based on hydrophillicity, accessibility and flexibility of 
amino acid residues. Additionally, fragments containing amino acids that are 
frequently found in experimentally validated linear epitopes (namely C, V and 
L) are given higher propensity scores (Kolaskar and Tongaonkar 1990). 
BPAP predicted a total of 15 fragments (Table 5) within the -16 to 286aa 
fragment (Figure 5.2), which was previously found to be sufficient for 9F4 
binding (Oh et al. 2010). The second method, BEPro predicts discontinuous 
epitopes based half sphere exposure calculation, solvent accessibility and 
side chain orientation information from available three-dimensional structure 
of proteins and assigns a score to each residue (Sweredoski and Baldi 2008). 
Most VN04 residues predicted as likely epitopes were situated close to each 
other and can be clustered within 11 antigenic fragments. Both methods 
predicted at least part of the previously identified epitope 256I/LVKK259 (shown 
in red in Table 5).  
Next three criteria were used to narrow down the epitopes to be tested. Firstly, 
since 9F4 is a homosubtypic MAb and does not bind H7 or H9 (Figure 3.3), 
we reasoned that residues conserved between H5 HA but not in either or 
both H7 and H9 are critical for 9F4 recognition. Secondly, critical residues 
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should be in close proximity (within a 12Å radius) to the 256I/LVKK259 in the 3D 
structure of H5. Thirdly, predicted fragments within the RBD were excluded 
since 9F4 does not inhibit hemagglutination (Oh et al. 2010). This process 
eliminated all but two predicted epitope sites (Figure 5.2, shown in green and 
orange) within the vestigial esterase subdomain of HA1, which were selected 
for further testing. We also included 19-34aa for further evaluation, although it 
is unlikely to be an antigenic site due to the distance from 256I/LVKK259 (Figure 
5.2, shown in blue). 19-34aa is located within the stem domain and is in close 
proximity to the HA2 fusion machinery. Thus, any interaction with 9F4, 
although unexpected, could explain the mechanism by which 9F4 prevents 




Antigenic fragments predicted by BPAP 
No. Residue number Sequence HA domain 
1 -12 to 6 IVLLFAIVSLVKSDQICIG SP/F 
2 19 to 34 IMEKNVTVTHAQDILE F 
3 38 to 62 NGKLCDLDGVKPLILRDCSVAGWLL VE 
4 69 to 82 EFINVPEWSYIVEK VE 
5 85 to 92 PVNDLCYP VE 
6 99 to 107 EELKHLLSR RBD/VE 
7 112 to 119 EKIQIIPK RBD 
8 125 to 140 HEASLGVSSACPYQGK RBD 
9 143 to 150 FFRNVVWL RBD 
10 170 to 177 EDLLVLWG RBD 
11 186 to 192 EQTKLYQ RBD 
12 196 to 202 TYISVGT RBD 
13 205 to 212 LNQRLVPR RBD 
14 248 to 258 IAPEYAYKIVK RBD/VE 
15 274 to 280 CNTKCQT F 
Antigenic fragments predicted by BEPro 
No Residue No Sequence HA domain 
1 1 to 15 DQICIGYHANNSTEQ F 
2 19 to 25 IMEKNVT F 
3 34 to 40 EKTHNGK F 
4 72 to 75 INVP F 
5 94 to 100 NFNDYEE VE 
6 103 to 110 HLLSRINH VE 
7 112 to 129 EKIQIIPKSSWSSHEASL RBD 
8 138 to 141 QGKS RBD 
9 151 to 171 IKKNSTYPTIKRSYNNTNQED RBD 
10 180 to 225 HPNDAAEQIKLYQNPTTYISVGTSTL RBD 
11 234 to 245 KPNDAINFESNG RBD 
12 255 to 261 KIVKKGD RBD/VE 
13 268 to 275 LEYGNCN VE 
 
Table 5: Antigenic fragments predicted using BPAP and BEPro. The 
previously identified epitope is shown in red. SP=Signal peptide, F=fusion 
domain, VE=vestigial esterase domain, RBD= receptor binding domain. 






















                                         
 
Figure 5.2 (continued from previous page): Predicted 9F4 epitopes  
(A) Sequence alignment of -16-286aa of Hatay04, VN04, NethH7 and HKH9. 
The numbering convention used is based on mature H5. Epitopes were 
predicted by either BPAP or BEPro and were selected for testing based on 
conservation within H5 HA but not H7 and H9 HA (shown in blue, green and 
orange). The previously identified epitope is shown in red. “*”  denotes amino 
acid conservation, “.” denotes semi-conserved substitutions, “:” denotes 
amino acid substitution within the same amino acid group. 
(B) PyMol ribbons schematic of VN04 HA monomer with HA1 unit shaded in 
light grey and HA2 unit in dark grey (Pdb ID: 2FK0). The surface of 
256I/LVKK259 is shown in red. Selected epitopes are conserved among H5 HA 
but not H7 and H9 HA. 60-62aa (in green) and 69-80aa (in orange) were 
selected for evaluation based on 3D proximity to 256I/LVKK259 (in red). 19-
34aa (in blue) was included in our evaluation due to its proximity to the fusion 
machinery (dark grey)  
 





5.3 N-terminal predicted antigenic site is not required for 9F4 binding 
Initially, N-terminal truncated mutants were created to rule out the 
involvement of predicted N terminal antigenic sites (Figure 5.3). As shown in 
Figure 5.4A,  9F4 bound to N- and C- terminal truncated mutants spanning 
16-286aa and 4 to 286aa, which could also be detected by polyclonal Rb-anti 
HA(N) in immunofluorescence assay, suggesting that deletions did not affect 
proper folding of the mutant Hatay04 fragments.  However, detection by Rb-
anti HA(N) is abrogated in the 14-286aa mutant, indicating that large N-
terminal deletions are deleterious. As a result, the involvement of 19-34aa 
was analysed using substitution or internal deletion mutations within the -16-
286aa mutant (Figure 5.3).  As shown in Figure 5.4B, 9F4 retained binding to 
internal substitution and deletion mutants spanning 19-34aa (-16-286 
I19A/M20A, -16-286Δ21-27 and -16-286Δ28-34) indicating that these 
residues are not involved in binding.  
9F4 was also screened against a combinatorial HA antigen library displayed 
on the surface of yeast. 9F4 bound to a total of 19 fragments (data not 
shown), all of which contained the 256I/LVKK259 epitope. The smallest binding 
fragment spanned residues 45 to 268 of mature H5 (Zhang L and Jiang L, 
personal communication, 2013). Collectively, the data suggests that the 
extreme N-terminal predicted fragments and HA2 are not essential for 9F4 
binding; and that additional residues upstream from 256I/LVKK259 contribute to 




   
Figure 5.3: Schematic of N terminal truncated, internal substitution and 







Figure 5.4: Predicted N terminal antigenic fragments do not contribute to 9F4 
binding. 
Full length Hatay04, (A) N-terminal truncated mutants, (B) internal deletion 
and substitution mutants were screened against 9F4 in immunofluorescence 
assay. The gene segments coding for the different mutants were generated 
by PCR and cloned into PXJ3’ vector and expressed in MDCK cells. The cells 
were fixed and permeabilized prior to exposure to antibodies. Binding by 9F4 







5.4 Two additional sites within the vestigial esterase subdomain are 
required for binding 
To evaluate whether the predicted 60-62aa and 69-8aa (Figure 5.2 in 
green and orange respectively) contribute to the final 9F4 epitope, triple 
alanine (AAA) mutants (Figure 5.5A) were constructed within full length 
Hatay04 HA to permit mutant HApp neutralization in future. The ability of 9F4 
to bind these mutants was screened in immunofluorescence assay. As shown 
in Figure 5.5B, positive immunofluorescence was only seen for Hatay04 and 
69AAA71 but not 60AAA62, 75AAA77 and 78AAA80. All mutants could be detected 




Figure 5.5 (continued on next page): Predicted epitopes spanning aa60-62 









Figure 5.5 (continued from previous page): Predicted epitopes spanning 
aa60-62 and aa75-80 are essential for 9F4 binding. (A) Schematic of triple 
alanine mutants tested. (B) Wild-type and mutant Hatay04 were screened 
against 9F4 in immunofluorescence assay. The gene segments coding for the 
different mutants were generated by PCR and cloned into PXJ3’ vector and 
expressed in MDCK cells. Binding by 9F4 or Rb anti HA(N) was detected by 
Alexa Fluor 488-conjugated secondary antibodies. 
 
5.5 256AA257 and 60AAA62 impair HA incorporation into HApp 
While attempting to create mutant HApp for the functional evaluation 
of 9F4 reactivity to these epitopes, it was discovered that the double alanine 
mutant 256AA257 [previously described in (Oh et al., 2010)] and 60AAA62 could 
not be detected by Rb anti HA(N) in HApp ELISA analysis (Figure 5.6) even 
though Rb anti HA(N) binding to 60AAA62 was observed when over-expressed 
in MDCK cells (Figure 5.5B) and previously described for 256AA257 (Oh et al. 
2010). In contrast, 69AAA71, 75AAA77 and 78AAA80 mutant HA could be 
detected in HApp, although binding is decreased compared to wild-type 
Hatay04 (p<0.05). Alanine mutants spanning the previously identified epitope: 
L256A, V257A and 258AA259 could be detected by Rb anti HA(N), albeit also at 
lower levels compared to wild-type Hatay04 (p<0.05). These findings imply 
that the 256LV257 motif as well as 60WLL62 are required for HA incorporation 




As shown in Figure 5.6, the irrelevant IgG control did not react with either 
wild-type or mutant Hatay04. 9F4 binding to HApp mutants L256A, V257A, 
258AA259 and 69AAA71 was detectable in HApp ELISA but were lower than the 
positive control Rb anti HA(N). In contrast, 9F4 binding to wild-type Hatay04 
HApp was higher than Rb anti HA(N), indicating that although mutations at 
these epitopes significantly reduced binding by 9F4, none of these epitopes 
alone completely abrogated HApp binding. In comparison, 256AA257, 75AAA77 
and 78AAA80 completely demolished 9F4 binding, suggesting that these 
epitopes are important for 9F4 binding.  
 
 
Figure 5.6: Effect of mutation on HApp binding. Equal amounts of HApp 
(based on p24 titre) expressing the wild-type and mutant Hatay04 were 
coated onto 96-well plates and detected using 1μg/ml 9F4. Incorporation of 
wild-type and mutant Hatay04 into HApp was checked using Rb anti HA(N). 
Results are normalized against pseudotyped particles devoid of HA. 










































Epitope mapping is the identification of amino acid residues and/ or 
sugars in an antigen that contacts the antibody paratope, which is formed by 
the variable regions of a given antibody. B cell epitopes are commonly 
classified as linear or discontinuous. Linear epitopes consist of consecutive 
amino acids while discontinuous epitopes are comprised of several scattered 
fragments along the primary protein sequence that spatially come together to 
form the complete antibody binding site in the tertiary or quaternary protein 
structure. The definition of neutralizing epitopes contributes to subunit 
vaccines and enables the selection of non-competing MAbs for combination 
passive immunotherapy (Clementi et al. 2012). Most B cell epitopes are 
discontinuous in nature and presents difficulties in epitope mapping by 
mutation analysis. Such epitopes are commonly defined by X-ray 
crystallography, which reveals entire epitope region and overall epitope 
conformation. Indeed, several discontinuous epitope structures of anti-HA 
MAbs have been mapped by x-ray crystallography. However, this approach is 
generally limited to Fab fragment- antigen complexes rather than whole 
antibodies due to the difficulties in obtaining whole antibody- antigen crystals 
(Corti et al. 2011; Ekiert et al. 2012; Sui et al. 2009). X-ray crystallography is 
also limited by the need for large amount of complexes for crystal formation 
and the identification of critical contacts still requires validation by mutational 
analysis under physiological conditions. This is classically performed by the 
generation of escape mutants; however, some mutations may lead to the loss 
of viral viability. Site directed mutagenesis of HA (alanine scanning) is an 
alternative approach but complete coverage of HA is time-consuming and 
care must be taken when interpreting results (Gershoni et al. 2007; 
Greenspan and Di Cera 1999). Other methods such as nuclear magnetic 
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resonance (NMR) and deuterium exchange mass spectrometry, which are 
useful for epitopes within small antigenic fragments (Thornburg et al. 2013), 
are not suitable for the mapping of the 9F4 epitope as the minimal contiguous 
amino acid sequence required for 9F4 binding is at least 250 amino acids in 
length.  
In this chapter, epitope mapping was guided by in silico antigenic prediction, 
sequence alignment with H7 and H9 HA and proximity of predicted antigenic 
sites to the previously characterized 256I/LVKK259 epitope. Expectantly, most 
antigenic fragments predicted by BPAP and BEPro are within the RBD. 
These were omitted in this screen as 9F4 does not prevent attachment. 
However, it is important to note that 256I/LVKK259 is located at the border of 
RBD and vestigial esterase subdomain. Thus it remains likely that some RBD 
residues may contribute to binding and site-directed mutagenesis of these 
residues in further experiments is required for a more complete analysis. 
In this chapter, we focused our attention on two predicted antigenic sites 
located within the non-RBD vestigial esterase domain. Using a combination of 
deletion and substitution mutants, two additional fragments 60WLL62 and 
75EWSYIV80 were found to be critical for 9F4 binding.  
Anti-H5N1 HA neutralizing antibodies can be broadly classified according to 
their binding sites: i) HA1 RBD, ii) HA1 non-RBD and iii) HA2 (Velkov et al. 
2013). Similar to H1 and H3 antigenic sites already described in Chapter 1, 
majority of the H5 neutralizing MAbs reported target the exposed HA1 RBD 
domain and correspond to sites A and B of H3 (Kaverin et al. 2007; Kaverin 
et al. 2002; Cao et al. 2012; Sun L. et al. 2009; Hu H. et al. 2012). These 
antigenic sites are highly variable due to the constant immune pressure and 
mutations within these regions correspond to phenotypic changes such as 
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altered virulence, immunogenicity and host adaptation (Chen Y. et al. 2009; 
Wang W. et al. 2010; Yen et al. 2009).  In contrast, only a handful of MAbs 
targeting non-RBD regions in HA1 have been described. These MAbs are 
less well understood, with some inhibiting the viral attachment step and 
others inhibiting post attachment events (examples shown in Chapter 1, 
Table 1.4). The novelty of these epitopes suggests that these MAbs could be 
suitable in combination approaches with RBD or HA2 targeting MAbs in a 
polyclonal passive immunotherapeutic fashion and further discovery and 
evaluation of MAbs within this obscure class is warranted. 
MAb 9F4 is an example of a neutralizing MAb targeting the non-RBD domain 
in HA1. From the results described in this chapter, MAb 9F4 is a conformation 
dependent antibody and the previously described 256I/LVKK259 epitope is 
necessary but insufficient for binding as the peptide fragment bearing 
256I/LVKK259 failed to react with MAb 9F4. Consistently, denaturation and 
reduction of full-length HA proteins greatly diminishes MAb 9F4 reactivity in 
western blot. However, weak binding could still be observed possibly because 
of protein renaturation or the close proximity of non-linear epitopes, as 
suggested for MAb AFluIgG01, which partially targets the non-RBD regions of 
HA1 (Cao et al. 2012). Intriguingly, although both 9F4 and AFluIgG01 target 
the HA1 globular head, they block the fusion process during virus uncoating.  
Here, we demonstrate that at least three distinct sites are critical for 9F4 
binding: 256I/LVKK259, 60WLL62 and 75EWSYIV80 (Figure 5.8). These three 
epitopes are well conserved among all human H5 sequences deposited in 
The Influenza Research Database (www.fludb.org). Only E75 is within a 4Å 
distance from 256I/LVKK259. Of note, mutation at this position (E75K) increased 
binding to α2,6Gal-linked sialic acid receptors in combination with at least one 
of the following mutations: S123P, N193K and R497K; but not alone (Yamada 
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et al. 2006). Molecular attributes have not yet been ascribed to the other 
epitope sites identified in this report. 
To our knowledge the 9F4 epitopes partially overlap with only two other anti-
H5 MAbs described: H5M9 (Zhu et al. 2013) and 4F5 (Zhang et al. 2013). 
H5M9 binds to a conformation dependent epitope and residues D45, E75, 
Y271 and N273 are critical for binding. Of these only E75 overlaps with 9F4 
(Zhu et al. 2013). 4F5 recognizes a linear epitope 60WLLGNP65 (Zhang et al. 
2013), which overlaps with 60WLL62 of the 9F4 epitope. The low occurrence of 
antibodies targeting this region suggests their rarity in the immune repertoire. 
One possible reason attributing to such immune sub-dominance could be that 
this region is not easily accessible within the homotrimeric structure of HA.  
The three 9F4 epitope sites map to the membrane distal vestigial esterase 
subdomain and cluster close to the 110-helix and the B-loop (Figure 5.7). At 
neutral pH, the 110-helix and B loop interact via a salt bridge and contribute 
to HA stability (DuBois et al. 2011). Binding of 9F4 around this position could 
therefore stabilize the pre-fusion HA conformation and provides a plausible 
explanation as to why 9F4 prevents fusion although it is situated away from 
the fusion peptide. 
Of the three antigenic sites contributing to the 9F4 epitope, 60WLL62 is not 
readily surface exposed (Figure 5.7). It is known that at low pH, HA1 
dissociates from HA2, however, there is no available structural information on 
the position of HA1 within the fusiongenic intermediates. It is likely that 
60WLL62 becomes more exposed during the transition from pre-fusion to post-
fusion forms and the association of 9F4 traps H5 in these intermediate 
conformations thereby preventing fusion.  
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The finding that mutation of 60WLL62 and 256I/LV257  (but not single mutants at 
aa256 or 257) abolishes incorporation of HA into HApp suggests that these 
epitopes could play a role in the packaging of progeny virions and are 
potential targets in preventing virus egress from infected cells. Budding is the 
final essential step of the virus life cycle and involves transport and assembly 
of all viral components at the apical plasma membrane of polarized epithelial 
cells, where sequential steps of bud initiation, elongation and release ensue. 
Although NA alone is sufficient for bud release and the formation of virus-like 
particles (Lai et al. 2010), co-expression with HA is required for the optimal 
association with lipid rafts for trafficking to the apical membrane (Ohkura et al., 
2014). HA is also required for the interaction with M1-RNP complexes 
(Barman et al., 2001). Additionally, HA membrane accumulation and 
association with lipid rafts orchestrates assembly of RNPs to the bud site by 
triggering mitogen-activated protein kinase (MAPK) signalling cascade via 
protein kinase C alpha, leading to induction of RNP export from the nucleus 
to the cytoplasm (Marjuki et al. 2006). The molecular determinants within HA 
contributing to its role in viral egress remain poorly understood. Therefore, the 
incorporation of these mutants within reversed engineered viruses will be 
useful in validating the role of these residues in virus packaging and egress 
under physiological conditions. Further fine mapping of 60WLL62 and 





Figure 5.7: Surface representation of 9F4 epitope sites on monomeric VN04 
(shown as ribbon diagram). HA1 is shown in grey and HA2 is shown in cyan. 
256I/LVKK259 (red) 60WLL62 (green) and 75EWSYIV80 (orange) are required for 
9F4 binding and cluster around the 110-helix (yellow) and B loop. Two 
rotational views are shown. The figure on the right is rotated 180o along the y-




CHAPTER 6: SUMMARY AND FURTHER STUDIES 
6.1 Overall approach and significance 
Since the 20th century, pandemic IAV has happened four times, each 
with varying severity and impact. For the purposes of pandemic alertness and 
response, the WHO describes the course of a pandemic in 6 phases (Figure 
6.1). A pandemic situation (phase 5-6) is declared when the virus fulfills all of 
the following criteria: i) an animal or animal-human reassortant virus has 
emerged in a naïve human population; ii) with the ability to infect and cause 
disease in humans, and iii) is characterized by community level human-to-
human transmission in at least two countries (WHO 2009). Both HPAI H5N1 
and LPAI H7N9 have fulfilled two of the three criteria. They are able to 
replicate in naïve humans and have fatality rates approximating 60% and 36% 
respectively (WHO 2014a; WHO 2014e). Although both viruses have not 
acquired the ability for sustained human transmission, limited transmission 
between close contacts have been observed (Butler 2006; Wang H. et al. 
2008). Neutralizing antibodies against the major surface glycoprotein HA is a 
crucial aspect to immunity, however HA is a “moving target” (Wang T. and 
Palese 2011) and this complicates pre-pandemic vaccines even within the 
H5N1 subtype alone. Despite sequence homology of >90% among H5 clades, 
there is little cross reactivity among neutralizing antibodies raised against H5 
(WHO 2011). In addition, the outbreak of H7N9 in China in 2013 highlighted 
that pre-pandemic preparedness against H5N1 alone is insufficient.  
The limitations of pre-pandemic vaccines and emerging resistance to 
currently approved antiviral drugs have renewed interest in antibody-based 
strategies. The gold standard of antibody strategies is to provide broad 
protection against multiple H5N1 clades and, ideally, cross protection against 
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other avian influenza subtypes as well. However, as potently neutralizing 
heterosubtypic MAbs are rare (Corti et al. 2011), the alternative strategy is to 
apply two or more non-competing MAbs for passive immunotherapy and is 
the basis of project. The application of a cocktail of MAbs enable 
neutralization synergy against viral quasispecies compared to single MAb 
formulations and has been demonstrated for several viral diseases including 
IAV H5N1 (Prabakaran et al. 2009), RSV (Caidi et al., 2012), SARS (ter 
Meulen et al. 2006) and HIV (Miglietta et al., 2014). This strategy requires the 
generation and pre-pandemic characterization antibodies. The methodology 
adopted for our laboratory is outlined in Figure 6.2. Through the combined 
effort of different laboratories, it is envisioned that a library of well-
characterized MAbs could facilitate selection of appropriate MAb mixtures for 
clinical trials and in the event of a pandemic situation. Additionally, anti-HA 
MAbs may be combined with MAbs that target other IAV proteins (discussed 
in Chapter 1) such that IAV infection may be intercepted at several stages of 
the virus life cycle.  
 
Figure 6.1: WHO phases of an Influenza pandemic. [Adapted from (WHO 
2009)]. Both H5N1 and H7N9 have reached pre-pandemic phase 3 and 
therefore present a real pandemic threat, requiring intervention strategies. It 
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is proposed that the pre-pandemic characterization of a library of neutralizing 
MAbs will facilitate rapid selection of a cocktail of MAbs in the event of a 
pandemic prior to the mass availability of new vaccines. 
 
 
Figure 6.2: Overall strategy adopted for the generation of different chimeric 
MAbs for combination passive immunotherapy.  
 
6.2 Summary of results and proposed further studies 
Using the method shown in Figure 6.2, 9F4, its chimeric forms and 
4F3 were characterized (summary provided in Table 6). Both 9F4 and 4F3 
displayed the ability to neutralize pseudovirus particles bearing H5 from 
clades 1, 2.1, 2.2 and 2.3.4, which have been reported to cause majority of 
human cases. In addition, 4F3 but not 9F4 neutralizes H7 HA from H7N7 and 
H7N9 subtypes, despite low sequence identity between H5 and H7. HA1 was 
sufficient for 4F3 binding while HA2 seemed to enhance 9F4 binding. The 
differences in binding profile suggest that these two MAbs target different 
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epitopes and could be complementary to one another. 9F4 displayed potent 
neutralizing capacity with IC50 and IC95 values approximating 0.01 μg/ml and 
between 0.1-1.0 μg/ml, respectively for the various H5 clades, comparable to 
other reported MAbs (Cao et al. 2012; Corti et al. 2011; Du et al. 2013). On 
the other hand, 4F3 activity could only be detected at relatively high 
concentrations.  
To reduce potential immunotoxicity reactions to mouse MAb, 9F4 was 
converted to two chimeric forms using molecular recombinant techniques. 
While xi-IgG1-9F4 retained comparable binding affinity and neutralizing 
potency of mouse 9F4, xi-IgA1-9F4 showed significant reduction in binding in 
ELISA and neutralizing assays. These results could imply direct participation 
by the Fc regions as described for other MAbs. Structural approaches such 
as cryoelectron microscopy may shed light on the overall antibody paratope 
without the need for large amounts of antibody-antigen complexes.  
In this study, we also report the direct in vivo effects of mouse 9F4 and xi-
IgG1-9F4 in both humanized and non-humanized mice. Neither MAb elicited 
strong cytokine responses in either of the mouse models, suggesting that the 
antibodies alone are not associated with adverse side effects. Further studies 
comparing both MAbs and xi-IgA1-9F4 in the context of infection is necessary 
to evaluate if Fc portions of different isotypes of 9F4 contribute to either 















1, 2.1, 2.2, 
2.3.4) 
and H7 HA 
0.625 μg/ml n.d. 10 μg/ml HA1 only 













n.d. 0.1-1 μg/ml 0.01 μg/ml 
xi-IgA1-
9F4 
1.25 μg/ml >1 μg/ml 0.1 μg/ml 
Table 6: Summary of MAbs evaluated in this report. (n.d. not done)  
Finally, the 9F4 epitope is conformation dependent and at least three 
antigenic segments, 256I/LVKK259, 60WLL62 and 75EWSYIV80 within HA1 
contribute to binding. Further studies using single alanine mutants are 
needed to narrow down the exact residues that are critical for 9F4 binding 
and neutralization. Antibody epitope mapping by escape mutagenesis is the 
classical approach for fine epitope mapping but was not performed in this 
report due to the lack of BSL3 facilities (Velkov et al. 2013). The attempt to 
generate escape mutants to 9F4 is now underway with new collaborators. 
Any escape mutants generated will provide added information on epitope 
sites and enable the evaluation of mutant fitness compared to wild-type. 
Epitope mapping by site-directed mutagenesis described in this study is 
complimentary to escape mutagenesis as epitopes crucial to viral viability 
cannot be identified by escape mutagenesis. 
Lastly, the 4F3 epitope will also be determined using similar methods. 
Cloning of 4F3 variable genes are underway and will be converted to chimeric 
IgG and IgA isotypes. It is expected that reformatting of 4F3 will reduce 
immunotoxicity and will enable better MAb penetration to sites of infection 
compared to parental IgM, however, retention of antibody activity must be 
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evaluated. As mentioned in Chapter 3, 4F3 could be a natural or early 
immune response antibody that has not undergone affinity maturation. Upon 
conversion to xi-IgG1-9F4, in vitro affinity maturation by error prone PCR may 
be attempted to increase the binding affinity of 4F3. The ability and 
concentration of the various forms of 4F3 required to protect mice from H5 
and H7 infection, both prophylactically and therapeutically will also be 
evaluated. 
In this report, we relied on molecular and cellular assays to characterize two 
broadly neutralizing H5N1 MAbs. These methods are qualitative or semi-
quantitative. Further work using biophysical methods such as surface 
plasmon resonance (SPR) or isothermal titration calorimetry (ITC) must be 
performed for quantitative analysis of binding affinity in the form of 
association and dissociation constants. These pharmacokinetic values will aid 
in predicting the efficacy of individual or a combination of MAbs in humans.  
6.3 Conclusion 
In conclusion, this report presents the characterization of two MAbs, 9F4 and 
4F3 that may be used in combination with other anti-H5 MAbs or MAbs 
targeting other IAV proteins for passive immunotherapy. The conversion of 
9F4 to chimeric IgG1 and IgA1 was successfully achieved. These chimeric 
MAbs retained varying degrees of binding and neutralizing activity against H5 
HA from multiple clades. 9F4 binds a novel conformation dependent epitope 
that has not been described previously, suggesting that it may be used in 
combination with other well-characterized anti-H5 MAbs. Finally, the ability of 
4F3 to cross-react with H7 is of interest and the specific residues contributing 
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Sequence and annotation of the immunoglobulin genes of MAb 9F4.  
The sequences of the A) VH and B) VL domains were obtained by RT-PCR 
performed on RNA extracted from the MAb 9F4 hybridoma. Sequences in 
bold, underlined and highlighted in grey represent variable (V), diversity (D) 
and joining (J) regions, respectively. These highlighted segments contain 
complementarity determining region (CDR) 1-3 and were cloned into vectors 
containing human heavy and light constant domains to form chimeric MAbs. 
 
